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DESIGN, SYNTHESIS, AND APPLICATION OF DUAL FUNCTIONING BODIPY 
PHOTOSENSITIZERS: A THERANOSTIC PHOTODYNAMIC APPROACH FOR 
CANCER THERAPY 




Development of concomitant photodynamic therapy (PDT) and photosensitizer 
fluorescence detection (PFD), termed theranostics, is of primary interest as combining 
the two modalities stands to offer a more personalized cost effective “see, treat, and 
monitor” approach. As a minimally invasive drug-device strategy, the standard protocol 
involves photosensitizer (light sensitive drug) or fluorophore administration followed 
by light activation. Specifically, PDT is an approved regimen for the treatment of non-
malignant and neoplastic disease. The cytotoxic effect derives from an activated 
photosensitizer reaction with local oxygen, which produces a tumor damaging species 
known as singlet oxygen.  PFD employs a fluorophore as an invaluable tool for 
monitoring photosensitizer bio-distribution along with delineating healthy and diseased 
tissue in the native environment. The two, PDT and PFD, are distinguished via 
competing photochemical mechanism of administered drugs, which in part hampers 
their combined application.  
 
A photosensitizer’s therapeutic efficacy is invariably linked to intersystem crossing, 
which attenuates fluorescence required for imaging.  Improving fluorescence yield of 
photosensitizer’s stands to impart information concerning drug location and 
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concentration. These parameters are vital for determining the optimal time of 
illumination within PDT.  Furthermore, fusion of PDT and PFD enables impromptu 
eradication of detected disease and subsequent monitoring of photodynamic response 
when targeted photosensitizers are used.  
 
This dissertation explores the design and synthesis of NIR dual functioning mono-
BODIPY photosensitizers for optical image-guided PDT. The synthetic methodology 
excludes conventional incorporation of halogens as heavy atoms, which alter 
photophysical properties. Moreover, identification of the key structure photophysical 
property relationship for obtaining both effective fluorescence and singlet oxygen 
generation was uncovered along with elucidation of the photochemical mechanism.   
Above all, application through fluorescence bio-distribution studies and whole body in 
vivo imaging facilitates more effective tumor ablation through optimizing drug-light 
intervals for PDT.     
 
The objective of this dissertation is to develop NIR BODIPY photosensitizers 
applicable for imaging and therapy with one PS. Chapter I describes ingenious efforts to 
develop NIR BODIPY dyes, yet none have surfaced as dual agents for fluorescence 
detection and therapy.  In addition, Chapter I highlight functionalization of NIR 
BODIPY dyes for improving water solubility, and tethering to cancer specific 
biomolecules.   
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In Chapter II, citing the weak fluorescence of porphyrin based PS and populated triplet 
state of BODIPY fluorophores, intersystem crossing and production of singlet oxygen 
was accomplished without the use of heavy halogen atoms such as Br and I. The heavy 
atom effect significantly reduces the fluorescence, thus limiting its dual-application.     
BODIPY and thiophene units were fused for extended conjugation with varying 
electronic effects. An investigation into the structure photophyscial property 
relationship concluded electron-withdrawing groups enable singlet oxygen generation 
absent conventional heavy atom incorporation. The lead compound, SBDPiR690 has an 
inherent brightness and phototoxic power of 26,400 M-1cm-1 and 50,400 M-1cm-1, 
respectively. The design and synthesis of several analogs resulted in an improved 
SBDPIR688 analog with a brightness of 37, 440 M-1cm-1 and phototoxic power of 
45,120 M-1cm-1. 
 
Chapter III demonstrates the translation of our lead compound SBDPiR690 photo 
physical properties in vitro and in vivo. Specifically, concentration dependence on cell 
survival illustrates minimal dark toxicity at the cell monolayer.  Furthermore, brightness 
of the parent compound proved advantageous for non-invasive imaging of bio-
distribution. The pharmacokinetic pattern helps establish an optimal drug light interval 
for vascular-targeted PDT, which was successful in total eradication of sub-cutaneous 
colon 26 tumor.    
 
In Chapter IV, we modify parent compounds through incorporating functional groups 
potentially facilitating improved aqueous solubility and overall improved 
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pharmacokinetics. The inclusion of ester moieties through substitution of the boron 
center disrupts singlet oxygen generation in our improved analog SBDPiR688. 
However, ester synthons at the peripheral sites of the lead compound SBDPiR690 
maintain its therapeutic capability through singlet oxygen generation. The ester 
functionality offers potential conjugation of target specific ligands for improved 









Chapter I. Introduction 
	  
Cancer is a disease characterized by the growth and proliferation of abnormal cells.1 
Among the five leading causes of death between 1958 and 2010 cancer ranked second 
to heart disease.2 However, heart disease fatalities have consistently declined, while the 
impact of cancer has remained by and large constant.3 According to this rate, it is 
probable cancer will soon become the leading cause of death (Fig. 1).  Advances in 
research, particularly sequencing of the human genome4, have afforded a better 
understanding of the tumor microenvironment and thus the evolution of malignant 
disease.  The causes of cancer are multiple and vary through exposure to carcinogens 
(e.g. chemicals, radioactive material, and viruses) that initiate aberration in proto-
oncogenes, which are biomolecules that control normal cell growth.5 Promotion of 
modified proto-oncogenes results in neoplastic lesions. The latter are transformed to 
clinical cancer and metastasis, which defines the progression of transformed cells.  
Overall initiation, promotion, transformation, and metastasis are the distinct phases of 
cancer evolution and is coined multistep carcinogenesis.6 
 
Chemotherapy and surgery are prominent treatments for eradicating the growth and 
proliferation of abnormal cells.  The gompertzian diagram below (Fig. 2) is a model of 
malignant tissue growth versus time in respect to established therapeutic modalities.7 
The red legend indicates tumor burden (cell growth), which can be diagnosed at 109 
cells, symptomatic at 1010-11 cells, and can be fatal at or beyond 1012 cells.  The blue 
legend represents infrequent rounds of chemotherapy with each reduction in tumor  
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Figure 1. Leading cause of death in the United States from 1958 to 2010.8 
 
burden signifying cell kill. However, the cell growth rate is greater than the rate of cell 
kill. Overall, infrequent rounds of chemotherapy at the symptomatic stage only prolong 
survival. The light blue legend represents frequent rounds of chemotherapy at the 
diagnostic stage. The cell kill rate is greater than the cell growth rate; however, the 
dosage is over an extended period of time. Surgical resection significantly reduces the 
tumor burden in a short span. Adjuvant chemotherapy is efficient at total eradication of 
tumor growth with frequent doses. The diagram clearly illustrates the effectiveness of 
surgery adjuvant chemotherapy, but of note is the considerable small margin between 
the diagnostic stage and fatality. Early detection is vital for therapeutic suppression and 















Figure 2. Modified gompertzian diagram of tumor burden versus time in respect to 
conventional therapy techniques.7, 9 
 
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) have 
been firmly established as diagnostic modalities.10 However, MRI exposes patients to 
large magnetic fields and is limited to macroscopic imaging.11 In contrast, PET is 
sensitive enough to diagnose at the microscopic level but involves the use of radioactive 
agents.12 Radioactive agents are known carcinogens.  Near IR fluorescence imaging is a 
sensitive technique for detecting and visualizing cells at the microscopic level.13 While 
it is limited in terms of resolving cellular events, the technique has been invaluable for 
demarcating malignant and normal cells during surgical resection.14 This technique, as 
well as its limitations, will be discussed more in depth within sections 1.5 and 1.6.    
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The established therapy modalities (e.g. surgery, radiotherapy, and chemotherapy) are 
successful at reducing tumor burden. However, patients often succumb to side effects. 
Surgical resection of organs and/or amputation of limbs can significantly alter patients’ 
lives. Furthermore, due to function of certain tissue and/or proximity to vital healthy 
tissue, surgery is not a habitual option. Radiotherapy seeks to offer selectivity of cancer 
cells through matching the geometry of tumor with radioactive beams despite radiation 
being a known carcinogen.15   Chemotherapeutic agents lack the ability to decipher 
between healthy and malignant cells. This manifests changes in physical appearances 
and poor prognosis (e.g. alopecia, pneumonia, and organ failure). Target-specific agents 
have demonstrated early clinical prominence, yet extensive investigations yield slight 
improvements in therapeutic outcomes.16 Moreover, the significant financial 
commitment and invested time for procuring novel agents are disparaging as drugs 
entering clinical and commercialization continue to decline.17 These facts and the 
persistent threat of cancer demand expansion of primary therapy regimens to include 
effective yet under-developed approaches.  
 
Theranostics is the combination of detection (diagnostic) and therapy concomitantly 
with the goal of achieving personalized medicine through real time monitoring and 
tuning of therapy and dose.  Theranostic Photodynamic Therapy was designed to 
improve prognosis and therapy due to its dual selectivity, use of non-ionizing material, 
and relatively low cost, yet it is not primarily considered.  Clinical and preclinical 
research aims to promote theranostic PDT through the development of near-infra-red 
(NIR) fluorescent photosensitizers as detection and therapeutic (theranostic) agents that 
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derive from inorganic (nano-particles) and organic scaffolds. The effort is attributed in 
part to the optical advantages associated with the “biological window” (700-900 nm) 
including minimal endogenous chromophore interference and reduced light scattering. 
Photofrin and Protoporphyrin IX, discovered by Doughtery18 and Kennedy19 
respectively, are among approved photosensitizers used for imaging and therapy of 
esophageal, bladder, and brain cancers.20   However, the optical properties are less than 
ideal, which limit their application and the expansion of theranostic PDT.  In addition, 
more sensitive agents are needed for detection of neoplasms and overall improvement 
of treatment and patient survival.21 Organic-based dyes such rhodamines, fluoresceins, 
and cyanines have proven to be advantageous in terms of imaging compared to 
porphyrin-based PS22 but fail to address theranostic photodynamic therapy limitations 
comprehensively. The difluoro-boroindacene family (4,4-difluoro-4bora-3a,4a-diaza-s-
indacene), abbreviated hereafter as BODIPY23, has earned increasing interest for 
excellent optical properties and is established as a versatile heterocyclic scaffold.24 
 
The central focus of this work investigates structural determinants of NIR BODIPY 
analogs for balanced fluorescence emission and singlet oxygen generation for overall 
effective brightness and phototoxic power. The work: 1) develops NIR dual-functioning 
photosensitizers through the variation of electronic properties, 2) elucidates the 
photochemical mechanism using transition absorption spectroscopy, 3) demonstrates 
application of dual functioning BODIPY photosensitizers for optical imaging and 
photodynamic therapy, and 4) incorporates reactive functional moieties enabling 
tethering of target-specific ligands. The following sections will discuss the intricacies 
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and current state of the art of PDT. In addition, select literature of BODIPY dye 
application as imaging and therapeutic agents is introduced in support of this approach 
to design brighter and more phototoxic BODIPY theranostic photosensitizers.     
 
1.1 Photodynamic Therapy (PDT) 
The photodynamic effect achieved in PDT derives via three essential components of 
light, photosensitizer, and oxygen.25 Individually none are therapeutic but together 
initiate a photochemical molecular oxygen reaction producing the cytotoxic singlet 
oxygen.26 The clinical protocol begins with administration of a photosensitizer. After 
sufficient time delay (drug-light interval), the PS ideally accumulates within the desired 
location, and light is focused to illuminate the target tissue (Fig. 3).27  
Figure 3.  Photodynamic therapy protocol27, reprinted with permission from [4]. 
Copyright (2010) American Chemical Society.  
 
Theoretically, the interaction of light and accumulated photosensitizer yields a singlet 
state photosensitizer (1PS).28 The excited state molecule internally converts and energy 














and yields a triplet state photosensitizer (3PS).  The latter process causes an antitumor 
effect via a type I or II mechanism.29 The type I mechanism is a direct PS reaction with  
biological molecules that forms radicals and subsequent superoxides.  The type II 
mechanism, the widely accepted photochemical process, involves an energy transfer 
from the triplet state PS to native oxygen at the diseased site to produce toxic singlet 
oxygen (Fig. 4).30
Figure 4. Simplified Jablonski diagram of type I and type II PDT cell-death 
mechanisms. 
 
The cell death mechanism, e.g. necrosis or apoptosis, is a direct result of the type and 
dose of PS used, drug-light interval, and dosimetry. PDT is believed to synergistically 
induce tumor damage through vascular hemorrhage, direct cell kill, and stimulate the 
innate immune system.30   The advantages of PDT are found in the ability to control the 
site specific dug activation; however, for primary clinical use, adequate improvements 
in light source and photosensitizer properties are needed. 
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Photosensitizer development and technological advances, which includes a multitude of 
devices such as light sources, delivery method techniques, and instruments for 
dosimetry, have driven and enabled the advancement of clinical PDT. Light sources are 
determined by PS absorption and ability to generate sufficient power to the disease 
location ergonomically with high efficiency.31 The conventional light dose consists of 
1-5 watts of power within the 630-850 nm wavelength range and irradiances up to 
hundreds of mW cm-2.32 The wavelength range, also known as the therapeutic window, 
is critical for optimizing tissue penetration of light as endogenous chromophores of 
hemoglobin derivatives and water can absorb incident light below and beyond this 
range.33    
 
Light sources have emerged primarily from three categories: broad emission filtered 
lamps, lasers, and light emitting diodes (LED). Early clinical treatments involved 
oversized argon-ion lasers, which are less than ideal for the clinical setting due to 
constant realignment with the target and the short wavelength emission bands.31 Solid-
state lasers have surfaced offering a more compact design while maintaining high power 
and the advantage of wavelength tunability; yet remain expensive and with many 
technicalities.34 Broadband emission lamps have the advantage of being applicable to all 
photosensitizers through the incorporation of narrowband and long-pass filters for 
absorption compatibility.35 However, broadband output and power are difficult to 
encapsulate within optical fibers. The latter is required to excite deep-seated tissues that 
are only accessible through biological orifices. Therefore, a large tradeoff exists 
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between broadband excitation and power. This limits lamp excitation sources to 
superficial lesions.36 
 
Recently, diodes lasers have been explored as viable options for photosensitizer 
excitation sources.  Diode lasers are compact, inexpensive, high powered, and cover 
visible to NIR absorptions. Conversely to lamp sources, diodes can be coupled with 
endoscopes for expansion of PDT to deep-seated malignancies.37 As diode lasers are 
state of the art, future advances include organic diodes and configurable diode geometry 
for matching targets. Furthermore, efforts are being made to reduce source cost, which 
could facilitate community and eventual home-care application.32 
 
1.3 Singlet Oxygen (1O2) 
The interaction of light, photosensitizer, and molecular oxygen results in photodynamic 
action through inactivation of viruses and cells.38 As shown in figure 4, singlet oxygen 
generated via the type II reaction is the final integral component responsible for an anti-
tumor effect. Prior to this reaction, quenching or deactivation of the lowest triplet 
excited state by molecular oxygen (O2) is required for production of singlet oxygen.39 
Singlet oxygen can exist in two states, (1Σg) and (1Δg), and both are formed in the event 
energy transferred from the triplet state is ≥ 157 kJ mol-1,  the energy of the upper 
excited state (1Σg).40 The lowest excited state of singlet oxygen, has an excited state 
energy of 94 kJ mol-1.  Upon formation of the highest state, the highly reactive but 




The efficiency of singlet oxygen generation is known as the singlet oxygen quantum 
yield (ϕΔ).42 This parameter is the prime indicator of a photosensitizer’s ability to cause 
a photodynamic effect.  The ϕΔ is an integer that exists between zero and one, with one 
representing the ideal case.  This scale has been established on the principle of one 
absorbed photon can maximally produce one molecule of singlet oxygen.  Again, the 
ideal case is every photon absorbed yields one molecule of singlet oxygen.42  
 
Many methods have been developed, tested, and applied for determination of the singlet 
oxygen quantum yield. Various techniques for accurate values include direct methods 
such as time resolved near-infrared luminescence and time resolved thermal lensing 
(TRTL).  The 1290 nm NIR emission of 1Δg allows it to be monitored directly by NIR 
luminescence.43 Conventional indirect methods for determined singlet oxygen quantum 
yields include chemical trapping and direct monitoring of O2 consumption.  Indirect 
techniques for determining singlet oxygen quantum yields are common in that the 
quantum yields can be determined without the use of expensive and specialized 
instrumentation.  In addition, most indirect chemical trapping methods, particularly 
oxygenation of 1,3-diphenylisobenzofuran (DPBF) and p-nitrodimethylaniline (RNO), 
are routine well-understood experiments due to considerable work elucidating singlet 
oxygen and acceptor mechanisms.44  
 
Monitoring of molecular oxygen consumption for singlet oxygen quantum yield 
involves measuring the oxygen concentration in the presence of a photosensitizer and 
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singlet oxygen acceptor before and after excitation. The acceptor essentially traps 
singlet oxygen produced via excitation of PS, and modifies the oxygen concentration in 
the system.  While ϕΔ is effective for assessing PS within the cell mono-layer, in vivo 
evaluation is better characterized by its phototoxic power (PP), which is the product of 
extinction coefficient (ε) and singlet oxygen quantum yield.25   
 
1.4 Photosensitizers  
Photosensitizers are the essential component in PDT.  While therapy through light drug 
interaction dates back to the mid 1800s, the current era of photosensitizer development 
was given birth through investigations of hematoporphyrin by S. Schwartz and R.L. 
Lipson at the Mayo clinic in the 1960s.20, 45 Lipson et al. were able to accomplish 
optimal tumor localization and enhancement of fluorescence diagnostic efficacy 
through purification of crude porphyrin. These efforts solidified the utility of porphryin 
as a diagnostic tool.  
 
Dougherty et al. later discovered hematoporphyrin derivative’s potential as a 
photosensitizer upon observation of partial and complete response to PDT.46 Such 
promising antitumor activity led to its commercialization as the first approved PS for 
Barret’s esophageal, cervical, papillary, endobroncheal, gastric, and papillary bladder 
cancers.47 Commonly known as Photofrin, it is one of the most widely used clinical 
PSs.48 While effective, Photofrin exists as a mixture of dimers and high oligomers, has 
lasting side effects such as skin phototoxicity, and sub-optimal absorbance at 640 nm.  
These limit Photofrin PDT’s application to deep-seated malignancies.49 
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These findings spawned the development of several second-generation photosensitizers, 
which have emerged to clinical trials attempting to surpass the shortcomings of 
Photofrin and meet the criteria of the ideal photosensitizer (Fig. 5). The ideal 
photosensitizers should 1) be chemically pure of a known composition with a 
reproducible synthesis for unambiguous interpretation of the overall effect, 2) have high 
extinction coefficient corresponding to the absorption in the NIR region 650 nm to 800 
nm, (3) demonstrate preferential tumor accumulation and retention in addition to rapid 
clearance from outside organs of interest facilitated by water solubility, stability, and 
hydrophobic character, 4) have high singlet oxygen quantum yield for PDT, and 5) have 
balanced singlet oxygen and fluorescence quantum yields for dual functionality i.e. 
tumor eradication and fluorescence detection.21, 25  
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Figure 5. FDA approved and current clinical trial first and second generation porphyrin 
based PSs.47, 50 
 
 
A new era of photosensitizer development is currently in effect as the design, synthesis 
and application of NIR target specific and/or activatable dual functioning 
photosensitizers are being investigated. Conjugating second-generation photosensitizers 
with tumor specific moieties such as folic acid, carbohydrates, and peptides or tethering 
to biologically active molecular beacons demonstrate encouraging photodynamic 
efficiency in vitro and in vivo.21, 51   However, investigations into active and passive 
targeting of photosensitizers by Pandey et al. concluded with emphasis on respective 
compounds’ partition coefficients i.e. lipophilicity contribute to enhanced permeation 
and retention of PS, which leads to more effective photosensitization.21   These structure 
activity relationship studies have provided pertinent information for the design of novel 




























1.5  Fluorescence Imaging  
The observation of human body systems with light is perhaps one of the most practiced 
imaging techniques in clinical and biomedical research as it enables characterization of 
intact tissue.52 Early clinical implementation involved the use of metal rigid 
bronchoscopes to visualize air passageways for detecting disease tissue. Many risk, 
such as the need for sedation, damaging of vocal cords, scratching and tearing of tissue 
led to the development of the first flexible fiber optic bronchoscope.53 Imaging 
capability further evolved upon incorporating an excitation light with the flexible fiber 
inventing a novel highly sensitive light induced fluorescence emission (LIFE) 
endoscopy technique.54 This method exposes tissues to a broad excitation spectrum 
(white light) and clinicians are able to observe the autofluorescence of normal/abnormal 
tissue for identifying gross morphology changes. Underpinning this technique is the 
optical properties of chromophores embedded within human tissue.  These 
chromophores vary depending on cell type and absorb light between 200 nm – 500 nm 
and have an emission spectrum over the 300 nm – 700 nm range.55 Clinicians ultimately 
excite the tissue of interest and obtain detailed functional and anatomical information.  
 
LIFE optical imaging has been revolutionized through the development of fluorophores 
as a means of contrasting or delineating regions of tissue of interest. Localization of 
exogenous fluorophores offers highly sensitive fluorescence detection of neoplastic 
lesions, including mapping of molecular events for retrieval of new biomarkers.27 The 
new state of the art has been fostered by the discovery, design, and synthesis of 
biocompatible fluorescent probes emitting light within the biological near infrared 
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window.22 Fluorophores offer advantages of stability and limited toxicity in contrast to 
radiolabeled compounds, which have limited half-lives and may cause exposure of 
ionizing radiation to both patient and clinician.  
 
Theoretically, fluorophores absorb light in the ground state (S0) and become excited to a 
singlet (Sn) state. Upon internal conversion to the S1 state, this excitation energy is lost 
through radiative decay given off as an emission light. The excited state can also 
intersystem cross (ISC) to a triplet state and decay by phosphorescence to the ground 
state (Fig. 6). Loss of energy by either or both pathways can be harnessed for imaging 
application.22 The florescence emission of molecules is characterized by the fluorescent 
quantum yield (Φflu).  This parameter is defined as the ratio of photons emitted to 
photons absorbed.42 However, fluorescence quantum yield alone is not adequate to 
characterize in vivo efficiency. The absorbance and emission efficiency should be 
considered for the design and application of fluorophores in vivo Brightness, the 
product of fluorescence quantum yield and extinction coefficient (Φflu x ε), is a more 
sufficient parameter to characterize fluorophores. The lone values of extinction 
coefficient or fluorescence quantum yield are often misleading, but their product is a 
comprehensive parameter to judge fluorophore effectiveness.    
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Figure 6. Simplified Jablonski diagram illustrating fluorescence imaging mechanism.  
 
Efforts to enhance NIR dyes have been focused on classes of cyanines, squarines, 
pthalocyanines, porphyrins, and BODIPY skeletons (Table 1). The Food and Drug 
Administration has approved indocyanine green as a fluorescent probe for retinal 
angiography.56 Despite its NIR absorption, ICG has a low quantum yield, (0.3% in 
water), lacks photostability, and is inert in terms of functionalization to biomolecules.57 
Improvement of photo/chemical stability, quantum yields, and water solubility of the 
mentioned alternative classes stands to yield more transparent information, as natural 
embedded chromophores are excluded by the near infrared excitation and emission.53, 58 
 
In addition to NIR optical properties, the ideal dye should be synthetically feasible with 
inherent reactivity for inclusion of functional groups.  IRDye800CW has established 
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with N-hydroxysuccinide.59 The reactive functional group allows tagging to receptor 
specific molecules for improved bio-distribution and target and tissue ratio.55 
 
Table 1. NIR fluorescent probes 22 









































Together, including the arrival of NIR lasers as ergonomic excitation sources and 
sensitive detectors32, these have expanded the limitations of conventional UV optical 
techniques from 1-2 millimeter surface and subsurface imaging to achieve imaging 
depths of several centimeters.55 However, fluorophores lack the ability to induce cell 






















































1.6 Photosensitizer Fluorescence Detection (PSFD), Guided Resection and PDT 
 The use of photosensitizers for imaging purposes facilitates a combinatorial approach 
for detection and therapy (theranostics) of cancer.  Photosensitizers primarily serve as 
therapeutics due to their high singlet oxygen generation.  However, garnishment of 
photosensitizer’s minor, but effective fluorescence provides means for accurately 
determining the gap between drug administration and illumination, examining PDT 
mechanisms, and marking therapy responses.27   
 
The two (PDT and PSFD) follow basic illumination principles but provide different 
outcomes through controlled light and photosensitizer dosages. For example Photofrin 
PDT serves to cause cell death with a drug concentration of 5.0 mg/kg while PSFD 
inflicts minimal to no cytotoxicity but instead fluoresces due to effective subtraction of 
background emission and photosensitizer concentrations of 0.25 mg/kg.27, 60 PSFD dates 
back to early 1900s where Policard observed preferential malignant accumulation of 
heamatoporphyin through its fluorescence.  Subsequent investigations into many first 
and second-generation photosensitizers have revealed innate ability to emit localized 
florescence and demarcate cancerous tissue upon illumination with UV light.61 The 
endogenous conversion of the prodrug aminolevulinic acid into protoporhyrin IX 
(PpIX) has emerged a primary PSFD agent.  PpIX is biologically formed in cells and 
chelated by iron as an intermediate via biosynthesis of hemoglobin. However, in most 
malignant tumors the chelation process by ferrocheletase is retarded. Administration of 
exogenous aminolevulinic acid mounts high concentration of PpIX where its 
fluorescence offers a stark contrast between healthy and malignant tissue.62 
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Photosensitizers primarily serve as therapeutics due to their high singlet oxygen 
quantum yield; however, the minor fluorescence capability has ushered the scaffold as a 
staple in surgery and PDT. The ability of porphyrin photosensitizers to localize and 
fluoresce optimizes surgical resection by visualizing small tumors with high sensitivity 
to define tumor and healthy tissue margins.63 This in turn allows for exclusive PDT of 
those tissues that cannot be surgically excised. This development was paramount for 
resection of cancerous tissue, as keen precision is needed avoid healthy tissue. Incident 
removal of healthy tissue can drastically alter patients’ quality of life and residual 
disease results in reoccurrence.64   
 
Photosensitizer fluorescence detection has become more frequent in clinical and 
medical procedures.27 This theranostic approach is invaluable for developing 
personalized methods to counter inadequate treatment outcomes and assist with  
identification of neoplastic lesions to bolster early detection, prevision of surgical 
intervention, and adjuvant therapy. 
 
1.7 Chemical Strategies for Producing NIR BODIPY DYE    
Advancements in the numerous fields of modern science and medicine have enabled the 
design of new fluorophores that can be illuminated within the red or near-infrared (NIR) 
region of the electromagnetic spectrum. These efforts have been aimed at visualizing 
intact biological tissue beyond the epithelial layer.  Fluorophores of fluorescein and 
cyanine have long demonstrated clinical efficacy, yet novel scaffolds and strategies are 
needed to overcome problems of currently approved dyes and to expand application of 
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fluorescence imaging in the clinic.65 Due to its advantageous photophysical properties 
and versatility for structural modification, BODIPY dyes have gained interest in 
attempts to translate these characteristics in biomedical application. 
 
BODIPY dye consists of a dipyromethene ligand chelated with a di-substituted boron 
atom, which is commonly a BF2 moiety. The joining of pyrrole units forms the 
dipyrromethene ligand via an interpyrolic methine bridge. BF2 chelation constrains the 
fluorophore to a fixed planar π-electron system. The structural uniqueness offers a high 
photostability with an intense absorption and emission profile, high extinction 
coefficient (40,000 to 80,000 M-1cm-1), and high fluoresence quantum yield > 0.60.  
Furthermore, BODIPY resists aggregation in organic solvent and is insensitive to pH 
and solvent polarity.23  
 
The typical BODIPY absorption profile exhibits a sharp UV band due to the S0-S1 
transition at 500-525 nm, a hypsochromic shoulder around 480 nm indicative of 
vibrational conversions, and a broad band peak at 375 nm attributed to an S0-S2 
transition.25 The emission band is located at 530-560 nm as an S1 to ground state 
transition. Due to a slow rate of intersystem crossing, phosphorescence is undetected.23 
The absorption profile can be shifted bathochromatically through modification of the 
BODIPY core (Fig. 7). The slightly polarized heteroatoms yield delta negative and 
positive reaction sites at varying positions on the internal zwitterionic core.66   The 
photophysical properties are a result of the nature, number, and location of added 
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substituents.  A number of BODIPY derivatives with red to NIR absorption profiles 









Figure 7. Structure of BODIPY core and its IUPAC numbering system.   
 
1.8  meso-Functionalization of BODIPY  
BODIPY core modification at the C-8 (meso) (Fig. 8) is facilitated by acid catalyzed 
condensation of the pyrrole unit with desired substituted acyl chlorides or aromatic 
aldehydes.67 Modulation of the meso-position with electro-neutral substituents has 
shown negligible affects to absorption and emission properties.68 A new class of 
BODIPY dyes termed aza-BODIPYs are the most successful BODIPY-based PDT 
agents to date. These derivatives, prepared by O’Shea et al. and functionalized by 
Burgess, are characterized by the exchange of the meso-carbon with nitrogen.69 The 
substitution increases the absorption maxima of the dyes by reducing the S0-S1 (π-π*) 
transition.  The absorption and emission bands are between 650-800 nm with a high 















capability through its minor but effective fluorescence (Φflu= 0.1). However, for 
noninvasive imaging of deep-seated malignancies, a higher fluorescence quantum yield, 
therefore brightness is desired.   
 
Direct substitution of the meso-position with an electron-withdrawing group is a 
hallmark of the keio-fluor (KFL) class of BODPIY based dyes.  This institutes a π-
donor π-acceptor mechanism, which is responsible for the observed bathochromic shift 
of absorbance and emission maxima. However, no therapeutic effect has been observed, 
and therefore KFL scaffolds are not applicable as theranostic agents.   
 
Figure 8. Structures of meso-substituted BODIPY. 
 
 
1.9 2,6-BODIPY Functionalization  
The 2,6- positions on the BODIPY core are prime for electrophilic substitution as these 
bare the least positive charge according to the mesomeric structures of the BODIPY 
core (Fig. 9).  Electrophilic substitutions of sulfonation, halogenation, and nitration 
have been established by Li70, Lee71, and Thivierge72 at the 2,6- positions.73 Inclusion of 
sulfonate groups has shown to improve water solubility with negligible effects to 














significant impact on the fluorescence quantum yield. The decrease in fluorescence is a 
result of the heavy atom effect in respect to halogenation and photo-induced electron 








Figure 9.  Resonance structures of BODIPY core illustrating the nucleophilic 2,6-
position. 
 
An alternative method of bathochromic shifting of the absorption profile involves 
extending the π-conjugation through palladium-mediated C-H functionalization for 
mono- and di- substitution products.72 This ideology has been established for the 
generation of hydrophilic molecules with functional moieties enabling bio-
conjugation.70, 72   
 
1.0.1  3,5-BODIPY Functionalization  
The acidic nature of methyl substituents at positions 3 and 5 has produced various styryl 
fluophores (Fig. 10). Knoevenagel condensation has afforded significant red shifts in 
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in a convenient one-step reaction.  As reported by Dehaen and Boens75, electron 
deficient BODIPY such as 3,5 dichloro undergo nucleophilic aromatic substitution as a 
means of functionalization and/or increasing the photophyscial properties (Fig. 10).  
Also BODIPY with 3,5-halogens are prime substrates for well-established transition 
metal catalyzed reactions such as Heck, Stille, Sonogashira, and Suzuki.23, 25 The above 
strategies have been demonstrated in the synthesis of novel BODIPY-based 
fluorophores applicable as biosensors and bio-labels.   
 
Figure 10.  Chemical structures of various 3,5-substituted BODIPYs. 
 
1.0.2 Modification of Boron Center  
Substitution of the boron center is advantageous for circumventing problems of parent 
BODIPY i.e. small stokes shifts and fluorescence quenching.  Replacement by aryl, 
ethynyl and alkoxide groups provide a class of highly fluorescent dyes identified by 
their substitution moieties as C-BODIPYs, E-BODIPYs, and O-BODIPYS76, 
respectively (Fig. 11).  The appendage of one or more polycycles to the boron center 
provides multiple light absorbing units to partner with the energy acceptor of the 
BODIPY nucleus.  Ziessel et al. have investigated the rapid energy transfer between the 
two fluorphores and have cited significant overlap of the donor polycycle emission and 
















the ethynyl substituents were negligible.  The dyes below are being explored as energy 
transfer cassettes and electroluminescent devices.   
 
Figure 11. Chemical structures of various boron substituted BODIPYs. 
 
1.0.3 Extended Conjugation Through Rigid Ring Fusion  
The generation of long emission BODIPY dyes has been accomplished through ring 
fusion.  The enhancement in emission derives from restricted bond rotation and steric 
hindrance. Ring annulation at the β,β’-position has surfaced as a solid strategy for 
generating BODIPY fused phenanthrene, spiro-fuorene moieties, and benzene from aryl 
fused-pyrroles and 2-acetyl-phenols as shown in figure 12.77 
 


















1.0.4 Biological Application of BODIPY Fluorophores   
 
Fluorophores conjugated to biomolecules i.e. proteins and peptides serve to elucidate 
various molecular pathways as these conjugates act as reporters of biological systems.78 
The compatibility of fluorophores with various bio-analytical and optical imaging 
techniques such as DNA sequencing, gel electrophoresis, in vivo imaging, vascular 
mapping, and nucleic acid detection allow characterization of subject biomolecules 
within intact tissue.      
 
As briefly mentioned in Chapter I, the emphasis on developing fluorophores with near 
infrared absorption and emission profiles revolves around the endogenous absorption 
and scattering of UV/visible light. Specifically water, lipids, oxyhemoglobin, 
deoxyhemoglobin and other biomolecules absorb UV and visible light, which hampers 
tissue penetration. UV illumination of these embedded molecules yield tissue 
autofluorescence and thus a low contrast between biological targets and surrounding 
tissue. Low energy near infrared light allows deeper penetration as the tissue extinction 
coefficient is significantly lower. Therefore, a significant increase in target-to-tissue is 
ratio established (Fig. 13).79 
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Figure 13. Autofluorescence of tissue in response to various excitation/emission filters; 
(GB:gall bladder, SI: small intestines, BI: bladder).57 Reprinted with permission from 
[51] Copyright (2003) Elsevier. 
 
As BODIPY dyes have excellent photophysical properties, translation of these attributes 
biologically has proven to be advantageous. The semi-porphryin scaffold has been 
applied as a biological label, reporter of enzymatic activity, sensor for metals ions and 




Figure 14.   Illustration of BODIPY biological application.  Reprinted with permission 
from [29]. Copyright (2008) American Chemical Society. 
 
1.0.5 Biological Labels 
In effort to comprehend the evolution and innovate treatment of disease, there has been 
an increased demand for substrates and tools to investigate bio-molecular interactions. 
As organisms do not emit a specific signal, fluorophore labeled biomolecules serve as 
unique and powerful tools for addressing this need. For example, biomolecules have 
been successfully tagged with fluorophores for intracellular and whole body imaging. 
However, this technique is limited to the efficacy of available fluorophores.   
 
BODIPY dyes are prime candidates as biological labels due to high fluorescent 
quantum yield, large absorption coefficient, and minimal dark toxicity. The reactivity 
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within the BODIPY structure enables facile conjugation of biological ligands such as 
nucleotides, amino acids, lipids, and proteins.  In general BODIPY-biomolecule 
conjugates are facilitated by conversion of terminal carboxylic acids to reactive motifs 
such as succinimdyl esters, maleimides, and bioorthoginal reaction partners (Fig. 15).  
 
Tethering of functionalized BODIPY to target specific ligands such as antibodies serves 
to visualize drug bio-distribution and detect receptor interactions. In addition, 
biomolecule conjugation can be accomplished with negligible effects to natural function 
due to small size of BODIPY. 
 
Many UV absorbing BODIPY based fluorophores are being used for live cell imaging.  
With the assistance of two-photon imaging, BODIPY based probes have been 
successful at imaging deeper intact-tissue.80 In vivo cellular labeling of sugars and 
amino acids has been reported utilizing copper free and copper facilitated click 
chemistry. BODIPY modified alkyne based probes were designed as non-perturbing 
“bio-orthogonal reporters” applied for labeling of azide modified surface glycans of 
CHO cells.81   
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Figure 15.  Structures of BODIPY with reactive functional groups. 
 
1.0.6 Enzyme Substrates  
Fluorometric assays are traditionally used to detect and analyze enzymatic activity.  
Assays measure the fluorescence difference between the fluorophore substrate and 
product for analyses of various enzymes.82 The ability to identify and understand such 
activity is vital to quantify enzymatic activity ex vivo. Conventional fluorophore assays 
of fluorescein and hemoglobin are often inconclusive due to the minute difference 
between substrate and product fluorescence.83 The optical properties of BODIPY are 
advantageous for enhancing analysis efficiency. Protease assays have employed the 
principle of Fluorescence Resonance Energy Transfer (FRET) for reducing proteins 

























fluorophores to proteins causes this reduction and upon hydrolyses the protein is able to 
fluoresce proportional to biological activity.85 
 
1.0.7 Environmental Indicators  
The tissue microenvironment provides a rich source of potential biomarkers such as pH 
and metal ions, which are indicative of disease onset. Design and synthesis of 
fluorescent sensors detecting deviation from regulatory levels have gained considerable 
interest over the past decade. These sensors arise from principles of Photoinduced 
electron and Internal Charge Transfer (PeT and ICT) incorporated into fluorophore 
spacer receptor constructs.  The receptor binds to an analyte causing a shift in 
fluorescence or wavelength absorption. In either applied principle, fluorescence 
emission is essentially reduced or shutoff preceding analyte binding.23 In the case of 
PeT, no spectral change is observed, however ICT is accompanied with significant 
spectral shifts.  BODIPY-based sensors have been developed with inherent PeT and 
ICT.  The sensors have been developed for monitoring imbalance in pH86, Zn2+87, Hg2+ 
Ni2+88, K+89, Cu2+ levels (Fig. 16).90  
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Figure 16.  Chemical structure of BODIPY dyes applied as bio-sensors. 
 
1.0.8  Cellular Stains 
Visualization of intracellular components is difficult due to their transparent nature.  
Thus investigation of the cell’s organelles through staining provides a visual aid for 
characterizing cellular morphology and function.91 BODIPY dyes applied for organelle 
staining is well established in the pre-clinical setting as their small size and appropriate 
amphilicity facilitate permeation and retention within cellular compartments, 
respectively.92 BODIPY dyes such as BODIPY TR-glibenclamide and BODIPY 
ceramide effectively stain the endoplasmic reticulum and Golgi apparatus accordingly.  
BODIPY conjugates, namely BODIPY FL-ceramide, BODIPY FL C5 –sphingomyelin, 











































live cell imaging and flow cytometry (Fig. 17).93  Overall the intracellular localization is 
not ffected due to the low molecular weight of BODIPY.   
 
Figure 17. Fluorescent BODIPY probes for endoplasmic reticulum and golgi apparatus 



















































Chapter II. Design, Synthesis, and Mechanistic Investigation of NIR Dual 
Functioning BODIPY PS  
1.0       Introduction  
Photodynamic therapy’s stagnant application as a primary treatment modality stems 
from a lack of photosensitizer development.  Since the worldwide approval of 
Photofrin, many disadvantages and guidelines for improvements in therapeutic efficacy 
have surfaced.  For example, Photofrin absorbs red light at approximately 630 nm, 
which does not allow tissue penetration beyond a few millimeters. At the above 
wavelength, the molar absorptivity (3,000 M-1 cm-1) is low, which necessitates extended 
and intense light dosage. These less than optimal properties limit Photofrin mediated 
PDT application to superficial tumors or those accessible by endoscope. Extended and 
intense light dosages along with slow clearance from skin post treatment causes skin 
photosensitivity.  Hence, the design of novel photosensitizers has been focused toward 
improving Photofrin’s shortcomings with the following guidelines:  (1) minimal toxicity 
absent illumination (i.e. no toxic effect without interaction with light)  (2) absorption 
within the biological window, (3) chemical purity, (4) high brightness for imaging, (5) 
high phototoxic power for therapy, and (6) appropriate lipophilic/hydrophobic balance 
for selective accumulation or possess functional groups for targeting. Many second-
generation photosensitizers have since been approved as their design seeks to follow the 
set guidelines.  However, none satisfy all criteria (Table 2).  Most approved PSs are of 











































































Table 2.  Optical properties of select 2nd generation PS. 
2nd Generation λabs ε  Φflu ΦΔ BT PP 
PSs  nm M-1cm-1     
M-
1cm-1 M-1cm-1 
PpIX50a, 94a 635 ~5000 0.16b 0.56 800 2,800 
 mTHPC95b 650 29,600 0.09 0.43 2,664 12,728 
HPPH96c 638 45,000 0.43 0.48 19,350 21,600 
BDP-MA97b 686 34,000 0.05 0.76 1,700 25,840 
Pc 498d 680 230,000 0.38e 0.43 87,400 98,900 
       
 
As a result of increasing cancer targets being subjected to PDT, new classes of PSs are 
needed to address the deficiencies of porphyrin scaffolds.  BODIPY (4,4-difluoro-4-
bora-3a, 4a-diaza-s-indacene) dyes are attractive as PSs due to their unique optical 
properties, in particular they possess high molar extinction coefficients and fluorescence 
quantum yields (Brightness).23 Singlet oxygen generation is atypical of BODIPY dyes 
due to ineffective intersystem crossing.  However, BODIPY dyes can be converted to 
photosensitizers through incorporation of heavy atoms. This phenomenon, known as the 
heavy atom effect, increases spin orbit coupling and thereby facilitates intersystem 
crossing and ultimately singlet oxygen generation.99 O’Shea et al. incorporated heavy 
atoms into the BODIPY core of tetraarylazadipyrromethanes (aza-BDP) to yield a 
singlet oxygen quantum yield of 0.74.99a, 99b, 100 However, further reports highlight that 
inclusion of heavy atoms results in cytotoxicity in the absence of light and compromises 
(i.e. shuts off) fluorescence yields due to increased intersystem crossing efficiency101 
(Fig. 19).  Thus, fluorescent BODIPY PSs without heavy atoms are preferred for 




Figure 19.  BODIPY PSs through incorporation of heavy atom halogens. 
 
This chapter reports our research work to develop an unprecedented case of BODIPY 
PSs without heavy atom halogen assistance. In the search for NIR BODIPY dyes, 
we discovered that SBDPiR690 possesses inherent and advantageous 
photophysical properties of singlet oxygen generation (ΦΔ = 0.42) and fluorescence 
quantum yield (Φflu = 0.22). The rare coexistence of these photophysical properties in 
conjunction with a high extinction coefficient (120,000 M-1 cm-1) afforded appreciable 
BT, 26,400 M-1cm-1, and PP, 50,400 M-1cm-1 and indicated this mono-chromophore’s 
potential as a dual functioning fPS for theranostics. 
 
The innate ability of SBDPiR690 to intersystem cross allows the use of BODIPY’s full 
compendium of photophysical properties for combined imaging and therapy. Drawing 
inspiration from this rare phenomenon within the BODIPY scaffold, we set out to 
identify the structural contribution for inducing intersystem crossing. Herein, the 
peripheral substituent affects on photophysical properties were analyzed to establish a 
BODIPY structure-photophysical property relationship – in particular, we validate the 
key factor for SO generation of these non-heavy atom-assisted	  BODIPY PSs through 

















2.1 Design and Synthesis of NIR Dual Functioning NIR BODIPY Analogs  
The design of the novel compounds, SBDPiR688, SBDPiR698, SBDPiR700 and 
SBDPiR710, was principled upon the serendipitous discovery of singlet oxygen 
generation by non-halogenated SBDPiR690. A structure photophysical property 
investigation reveal analogs possessing oxygen at the peripheral sites are incapable of 
producing singlet oxygen (Table 3). This finding is attributed to the strong donating 
character of the atom. Therefore, agents were designed to incorporate substituents with 
modulated electron donating groups at the peripheral positions as in SBDPiR710 and 
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Scheme 1.  Synthesis of NIR BODIPY PS.   
 
 















































 SBDPiR688 R= CF
3 
28% 
 SBDPiR698 R= F 32% 
 SBDPiR710 R= CH
3
 43% 
 SBDPIR700 R= CN 37% 
 SBDPiR690 R= H 60% 
 SBDPiR731 R= OMe 50% 
 SBDPiR740 R= OH 54% 
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2.2 RESULTS AND DISCUSSION  
The starting point of our synthesis was the reaction of commercially available 
bromothiophene carboxyaldehyde 33 and ethyl azido acetate 34 in the presence of 21% 
sodium ethoxide to promote an aldol dehydration reaction (Scheme 1).102 The 
intermediate, (Z)-ethyl 2-azido-3-(5-bromothiophen-2-yl)acrylate, was not 
characterized, but dissolved in toluene at 100° C for 1 h to yield the five membered 
cyclized product 35.   Hydrolysis of the 35 by 15 equivalents of sodium hydroxide 
afforded 36 in high yields. These conventional synthetic reactions provide the building 
blocks to an invaluable thieno-pyrrole-fused key intermediate BDP635.  This 
intermediate was recently established as an efficient platform for developing NIR 
multifunctional agents.102 The red emitting dye was synthesized through a one-pot TFA 
mediated decarboxylation of 36 at 45° C followed by condensation of TFA anhydride to 
obtain the CF3 meso-substituted dipyromethane unit. Chelation of dipyromethane with 
boron trifluoride followed by purification via flash chromatography yields the BDP635 
with a yield of 16%.102 The conjugated-π framework and peripheral bromines give rise 
to a powerful electrophile that is ideal for Suzuki-Miyaura coupling reactions.   
 
 
Compounds BDP635, SBDPiR690, SBDPiR731, and SBDPiR740 were synthesized in 
a previous study [Chemistry An Asian Journal 2013, 8,3123-3132] and repeated for 
control studies.  The novel compounds, SBDPiR688, SBDPiR698, SBDPiR700 and 
SBDPiR710, were synthesized according to Scheme 1. In an one-pot reaction, BDP635 
and the respective commercially available aryl-boronic acid were dissolved in a 
biphasic mixture under reflux 80° C to achieve the reported analogs. The reaction times 
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and yields varied between 2-4 hours and 60-32% respectively. This is a direct para – 
substituent effect as electron-withdrawing groups deactivate the phenyl ring of the aryl 
boronic acids.  Reaction completion was judged by a distinct color change as extending 
the conjugation bathochromatically shifts the emission. This proved advantageous for 
synthesizing electron-withdrawing analogs.  The compounds were purified via column 
chromatography on silica gel prior to spectroscopic and biological analysis. Suzuki 
coupling hallmarks of easily separated inorganic starting material and bi-products are 
evident with the pure 1H NMRs. We further characterized each analog through high-
resolution mass spectrometry.  	  




Figure 21. ORTEP view of the X-ray crystal structures of SBDPiR690.  
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Displacement ellipsoids are drawn at the 50% probability level. 
 
The X-ray crystal structure was obtained at the University of North Texas.  The X-ray 
crystal structure of SBDPiR690 confirmed its structural similarities with that of 
dibromo-intermediate (BDP635)102. The molecule crystallized in the monoclinic crystal 
system with space group P21/c. The five core fused rings were almost planar (Fig. 21). 
The conjugated nature of the middle ring was confirmed by the comparable bond 
lengths of between C7-C6 (1.396 Å) and C7-C8 (1.393 Å); between C6-N1 (1.398 Å) 
and C8-N2 (1.392 Å); and between N1-B1 (1.509 Å) and N2-B1 (1.526 Å). The boron 
center also maintains tetrahedral geometry with an N1-B1-N2 angle of 105.7o and an F-
B-F angle of 108.5o. Two phenyl groups, although rotatable in a solution, were also 
close to the same plane with the main core. The dihedral angles of S1-C3-C14-C15 and 
S2-C11-C20-C25 were 11.6 o and 15.4 o, respectively. 
 
2.4 Optical Properties  
The absorption and emission spectroscopic data are presented in Table 3. The SBDPiRs 
exhibited the signature sharp absorption characteristic of BODIPY dyes indicative of 
the S0 – S1 transition (Fig. 22). The varying substituents impacted the absorption and 
emission maxima. SBDPiRs with electron donating groups (CH3, OMe, OH) have red-
shifted maxima compared to SBDPiRs with electron withdrawing groups (F and CF3) – 
λabs = 688, 698 vs. 709 ~ 738 and λflu = 695, 705 vs. 712 – 763. The bathochromic 
shifts by electron donating groups was evident – 21 ~ 50 nm shift in λabs of and 12 ~ 
63 nm shift in λflu from those of BDPiR690. It is perhaps due to a better push/pull 
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system between pull group (CF3) at the meso position and push group (OH, OCH3, and 
CH3 groups) at the para-position of the phenyl groups23. In addition, this correlation was 
manifested in the Stokes shift.  SBDPiR688 absorbance to emission shift was relatively 


















Figure 23. Fluorescence spectra of SBDPiR 
 








































Singlet oxygen quantum yield is defined as the ratio of molecules of singlet oxygen 
generated over photons absorbed.  The value was determined by measuring the 
phosphorescence of singlet oxygen after the excitation of BODIPYs102 The electronic 
properties of the para-substituents demonstrated positive and negative effects in respect 
to SO generation. While SBDPiRs with electron donating groups (CH3, OH, and OMe) 
did not show any detectable ФΔ, SBDPiRs with electronic withdrawing groups (F and 
CF3) exhibited moderate ФΔ (0.20 and 0.47).      
 













SBDPiR690 H 688 700 120,000 0.22 0.42 26,400 50,400 
SBDPiR688 CF3 688 695 211,000 0.39 0.47 82,290 99,170 
SBDPiR698 F 698 705 146,000 0.38 0.20 55,480 29,200 
SBDPiR700 CN 700 715 146,251 - - - - 
SBDPiR710 CH3 709 712 287,000 0.67 ND 192,290 ND 
SBDPiR731 OCH3 731 755 185,000 0.38 ND 70,300 ND 
SBDPiR740 OH 738 763 160,000 0.10 ND 16,000 ND 
[a] Molar absorptivity measurements were carried out in CHCl3 except BDP740-OH 
performed in EtOH. [b] The fluorescence quantum yield was determined in CHCl3 
(MeOH for BDP740-OH) at 298 K with Aza BODIPY Фflu = 0.34.  [b] Quantum yields 
determined in CHCl3 at 298 K with KFL-4 as reference. [c] SO quantum yield was 
determined in CHCl3 with [Ru(bipy)3]Cl2 as a reference (ФΔ  = 0.77 in MeOH). [d] Not 
determined under our experimental conditions. ND: Not Detected. [e] Brightness (= ε × 
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Фflu)   [f] Phototoxic Power (= ε ×  ФΔ) [f] Фflu for SBDPiR688, -698 is 0.39 and 0.38 
with respect to ADPBBF2 (0.34).   
 
In comparison to Фflu and ФΔ, BT and PP are better parameters for judging  
fluorescence imaging and PDT capability as these consider the extinction coefficient of 
PSs: BT = ε × Фflu and PP = ε × ФΔ 102. Light harvesting is critical in particular for in 
vivo conditions where the excitation light is extremely limited due to the light 
attenuation by tissues. The BT and PP of electron withdrawing analogs SBDPiR690, 
688, and 698 were higher than those all second generation PSs in Fig. 1 except Pc 4.  
These optical characteristics are good indicators of the potential as dual functioning 
fPSs. SBDPiR688 showed excellent BT and PP comparable to those of Pc 4. 
 
2.5 DPBF Method for Detection of Singlet Oxygen  
The analogs present were investigated for singlet oxygen generation. Tetrahydrofuran 
(THF) solutions of the novel SBDiRs were irradiated with broadband light, 400-850 
nm, at 0.5 mW/cm2.  Singlet oxygen generation was approximated experimentally 
through the oxidation of 1,3-diphenylisobenzofuran (DPBF), a known singlet oxygen 
scavenger.  The presence of reactive oxygen species such as singlet oxygen causes an 
evident decrease in the DPBF absorbance band at 410 nm.   The initial concentrations 
were 5 x 10-6 M of SBDPiR and 90 x 10-6 M of DPBF over a period of 16 min. 
SBDPiR690 was shown in our previous study to have a high singlet oxygen quantum 










Figure 24. Time-dependent decrease of absorbance (410 nm) by oxidation of DPBF (90 
x 10 -6 M) with SBDPiR (5 x 10-6 M) under broadband light (400-850 nm at 0.5 
mW/cm2).   
 
While SBDPiR710 rate of DPBF oxygenation is subtle at 0.5 fold, analogs 
SBDPiR688, SBDPiR700, and SBDPiR698 demonstrate folds of 1.0, 2.0, and 2.5 
respectively.  The less significant rate associated with SBDPiR710 is due hypothetically 
to the persistent electron donating effect of the -CH3 substituent. Again, this trend was 
visualized in our initial study, as 1O2 for SBDPiR731 and -740 were negative.  Further 
validation was obtained by the phosphorescence spectra of 1O2 at 1270 nm.  The 
intensity of the respective 1270 nm peaks align with the DPBF data illustrating 
SBDPiR688 > SBDPiR698 in respect to singlet oxygen generation efficiency. 
SBDPiR710 was not detected in the spectrum, indicating no singlet oxygen generation. 
Noteworthy is the relatively high fluorescence quantum yield (Φflu) ~ 0.77 for both 
singlet oxygen generating analogs. This demonstrates their ability to transition between 

















both S1 to S0 and S1 to T. These coexisting optical characteristics are of primary 
importance for developing theranostic agents.  
 
2.6 Electrochemical Potential.  
The redox potentials of all SBDPiRs were determined by Dr. Francis D’souza at the 
University of North Texas. The electrochemical potentials were measured in CH2Cl2 
containing 0.1 M TBAP with Ag/AgCl as a reference electrode and 
ferrocence/ferrocinium (Fc/Fc+) as an internal redox standard (Table 4). Excluding 
SBDPiR740, all SBDPiRs underwent two completely reversible redox potentials 
forming the respective stable anion(s) and cation(s)102. Cyclic voltammograms of the 
new analogs showed the oxidation potential range from E1/2 = 0.78 to 1.22 V and the 
reduction potentials between E1/2 = -0.76 to -1.51 V. 
 
In our initial study102, we discovered a natural relationship between the energy gap of 
first oxidation and reduction potentials with ФΔ. BDP635 (dibrominated intermediate) 
and SBDPiR 690 had the largest energy gaps between the redox potentials, 1.77 and 
1.72 V. These two exemplify appreciable SO generation (ФΔ > 0.2) among 12 analogs. 
The energy gaps of the remaining analogs were smaller, ranging from 1.57 to 0.92 V. 
Interestingly enough, the large energy gap, 1.58 and 1.70 V, is persistent in the two new 





2.7 Mapping of HOMO-LUMO Energy Levels 
We estimated the HOMO and LUMO energy levels of the two groups of BODPY 
analogs – with electron withdrawing groups (SBDPiR688 and 698) or electron donating 
groups (SBDPiR710, 731, 740) – from their first oxidation and reduction potentials 
(Table 4), mapped in the graph (Fig. 22). The standard method equation EHOMO/LUMO= (-
4.78 + (E1/2ref vs. Ag/Ag+ (–E1/2OX/RED vs. Ag/Ag+) was used to calculate the energy levels where -
E1/2ref = is the half potential of ferrocene vs Ag/Ag+.103  The HOMO energy levels of the 
analogs with electron donating groups decreased by -0.10, -0.19, and -0.23 eV while the 
decrease of the analogs with electron withdrawing groups was much smaller, by -0.01 
and -0.15 eV, compared to the HOMO energy level of SBDPiR690. The HOMO-
LUMO energy gaps of SBDPiRs with electron withdrawing groups also were larger, 
1.70 and 1.66 eV, than those of SBDPiRs with electron donating groups, 1.34 ~ 1.53 
eV.  
 
The relation between the HOMO-LUMO energy gap and ФΔ of all BODIPY analogs 
(including analogs in our previous reference102 we have prepared) was plotted (Fig. 25). 
Even though we could not identify a single equation covering the relationship for all the 
compounds in our previous study and current works, there was a noticeable trend. It 
appears > ~1.5 eV of HOMO-LUMO gap is necessary for our BODIPY analogs to 
exhibit appreciable SO generation (ФΔ > ~0.2). This trend alone does not suffice for the 


















[a] Half potentials of first oxidation and reductions  
EHOMO(Fc)=  -4.78 eV 
E1/2 ox (Fc)= 0.40104 
[b] EHOMO = -4.78 + (E1/2 ox (Fc)-(E1/2ox)); [b] ELUMO = -4.78 + (E1/2ox(Fc)-(E1/2red))103 
[c] Egap = EHOMO-ELUMO 
 
 
Figure 25.  a) Mapping of HOMO LUMO energy levels, b) Critical HOMO-LUMO 
energy difference threshold required for ≥ 0.2 SO quantum yield. 
 




































SBDPiR690 H 0.79 -0.93 -5.17 -3.45 -1.72 
SBDPiR688 CF3 0.94 -0.76 -5.32 -3.62 -1.70 
SBDPiR698 F 0.78 -0.80 -5.16 -3.50 -1.66 
SBDPiR700 CN - - - - - 
SBDPiR710 CH3 0.69 -0.84 -5.07 -3.54 -1.53 
SBDPiR731 OCH3 0.98 -0.45 -5.36 -3.93 -1.43 
SBDPiR740 OH 1.02 -0.32 -5.40 -4.06 -1.34 
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2.8  Time-resolved Transient Absorption Spectra  
Transition absorption experiments were performed by Dr. Francis D’souza. In order to 
study the triplet state of SBDPiRs, we recorded time-resolved spectra of SBDPiRs 690 
and 731105. For both compounds, significant bleaching band was detected in the 
femtosecond transient absorption spectra (A and B), at 708 nm and 726-754 nm, 
respectively, due to the depletion of ground state SBDPiRs (Figs. 26 and 27). In the 
nanosecond transient absorption spectra (C and D), positive absorption peak was 
observed at 594 and 550-650 nm for SBRPiRs 690 and 731 nm, respectively, 
presumably due to the absorption of triplet species of these dyes (Figs. 28 and 29). 
Interestingly, transient bands of the triplet-excited state were persistent for nearly 50 ms 
in the case of SBDPiR731 compared to about 3 ms of 690 (Figs. 30 and 31). Since 
longer triplet lifetime is preferred for SO generation, we hypothesize that the 
determinant factor for SO generation of, at least, these two dyes is not triplet state 
lifetime, but possibly the quantum yield of triplet state, the other key factor of ΦΔ. 
Detailed spectral studies are underway to prove this hypothesis, which will be presented 











Figure 26.  Femto-second spectrum of SBDPiR690 at the indicated time intervals in 
oxygen free benzonitrile. 
 
 




















Figure 27. Femto-second spectrum of SBDPiR731 at the indicated time intervals in 




























Figure 28. nano-second transient absorption spectrum of SBDPiR690 at the indicated 
















































Figure 29.  nano-second transient absorption spectrum of SBDPiR731 at the indicated 





























Figure 30. Decay profile of SBDPiR690 after nanosecond pulsed excitation at the 

























Figure 31. Decay profile of SBDPiR731 after nanosecond pulsed excitation at the 























2.9 Conclusion  
Photodynamic therapy’s clinical use has been hampered due to less than ideal 
photosensitizers.  The BODIPY class of dyes have shown promise to overcome the 
limitations set by approved photosensitizer classes such a porphryins and 
pathalocyanines. Until now, it was of conventional practice to design potential BODIPY 
photosenistizers to incorporate (1) extended conjugation with π-donor and π-acceptor 
substituents in hopes of visible to near infrared absorption (2) inclusion of the heavy 
atom effect i.e. coupled Br, I, for induction of intersystem crossing and subsequent 
triplet state to 1O2 generation (3) A resonance energy transfer between dimers, dyads, or 
triads of BODIPY dyes and sensitizers for broad band absorption in the visible region 
and 1O2 generation.  Heretofore even as recent as the year 2013 and 2014, the scientific 
community insists the HAE must be incorporated within mono-chromophore BODIPY 
dyes for ISC i.e. through spin orbit coupling.106, 107  
 
We successfully demonstrated that monomeric BODIPY-based dyes can generate 
singlet oxygen without heavy atom effect and the efficiency of singlet oxygen 
generation can be modulated by the substituents. From the structure-property 
relationship analysis of these SBDPiRs, we observed that the electron withdrawing 
groups at the aromatic ring increased both HOMO-LUMO energy gap and singlet 
oxygen quantum yield. More noticeable was that the SBDPiR photosensitizers also 
showed moderate brightness, which makes these suitable for the optical image-guided 
PDT. The transition absorption spectroscopy offers details mechanistic evidence of 
intersystem crossing absent heavy atom contribution.   
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2.0.1  Experimental and General Methods 
2.0.2 (35) Ethyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate102: Ethyl azidoacetate 
(31.0 g, 240.31 mmol) and 5-bromothiophene 2-carboxyaldehyde (11.5 g, 60.0 mmol) 
were dissolved in absolute ethanol (500.0 mL) under ice at -15 °C for 25 min.  A 21% 
ethoxide solution (0.089 L, 240.0 mmol) was added dropwise to the mixture and stirring 
continued for 2 h.  A saturated solution of ammonium chloride was added to yield a 
yellow precipitate, which was collected by filtration and dried.  The resulting brown 
residue was dissolved in toluene and allowed to reflux 2 h. The solvent was evaporated 
and purified by column chromatography (silica gel) using gradient elution of 
ethylacetate: hexane (5-30:95-70) to obtain a brown solid, yield 75%.  1H NMR (300 
MHz, CD2Cl2) δ 1.38 (t, J = 7.2 Hz, 3H), 4.37 (q, 2H), 7.03 (s, 1H), 7.04 (s, 1H), 9.18 
(br s, 1H). ethyl 2-bromo-4H-thieno[3,2-b]pyrrole-5-carboxylate (35) has been 











Figure 32.  1H NMR of compound 35 
 
2.0.2  (36) 2-Bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid 102: Ethyl-2-bromo-4H-
thieno[3,2-b]pyrrole-5-carboxylate (35) (5.0 g, 18 mmol) was dissolved in ethanol 
(100.0 mL).  Sodium hydroxide (11.0 g, 0.28 mol in water (50.0 mL) was added under 
reflux for 1.5 h.  The reaction was cooled to room temperature and then chilled in ice to 
acidify mixture with concentrated hydrochloric acid.  The precipitate was filtered and, 
washed with water and dried. 36 was obtained as a dark green solid (3.7 g, 82%).  1H 
NMR (300 MHz, CD2Cl2) δ 6.94 (s, 1H), 7.12 (s, 1H), 11.99 (s, 1H). (36) has been 
previously reported and was synthesized by the literature with minor modifications.105 
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Figure 33.  1H NMR of compound 36. 
 
2.0.3 (BDP635) 2,8-Dibromo-5,5-difluoro-11-(trifluoromethyl)-5H-thieno[2',3':4,5] 
pyrrolo [1,2-c] thieno[2',3':4,5]pyrrolo[2,1-f][1,3,2]diazaborinin-4-ium-5-uide102: 2-
Bromo-4H-thieno[3,2-b]pyrrole-5-carboxylic acid (51) (2.0 g, 8.1 mmol  SFs!!) was 
dissolved in trifluoroacetic acid (25 mL) and stirred at 40 °C for 30 min. Trifluoroacetic 
anhydride (15 mL) was added and the mixture stirred at 80 °C for 6 h forming an 
intense blue color. After cooling, the reaction was poured into saturated aqueous 
NaHCO3 solution to neutralize. The formed precipitate was filtered, washed with water 
and dried in vacuo.  The resulting compound (52) was dissolved in dichloromethane 
(500 mL), boron trifluoride diethyl ether complex (7 mL) and triethylamine (5 mL) 
were added to stir for 1 h.  The reaction mixture was added directly to silica gel (eluent 
CH2Cl2) for purification to obtain (BDP635) as a bluish green metallic solid (0.215 g, 
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5%). 1H NMR (CD2Cl2, 300 MHz): δ=7.3 (s, 2H), 7.2 (s, 2H); BDP635 has been 
previously reported and was synthesized by the literature with modification.105 
 
Figure 34.  1H NMR of BDP635. 
 
2.0.4 (SBDPiR690) 5,5-Difluoro-2,8-diphenyl-11-(trifluoromethyl)-5H-thieno 
[2',3':4,5]pyrrolo[1,2-c]thieno[2',3':4,5]pyrrolo[2,1-f][1,3,2]diazaborinin-4-ium-5-uide 
102: 1H NMR (CD2Cl2, 300 MHz): δ 7.8 (s, 1H), 7.7 (s, 1H), 7.6 (d, J = 8.0 Hz, 4H), 
7.5 (s,1H), 7.4 (peaks overlap, 7H). HRMS EI (m/z): Calculated for C26H14BF5N2S2 
524.0612; Found: 524.0599 [M]+. SBDiR690 has been previously reported and was 











uide 102: 1H NMR (CD2Cl2, 300 MHz): δ 7.8 (d, J = 8.0 Hz, 4H), 7.3 (s, 2H), 7.3 (s, 
2H), 7.0 (d, J = 8.0 Hz, 4H), 3.9 (s, 6H); HRMS EI (m/z): Calculated for 
C28H18BF5N2O2S2 584.0823; Found: 584.0825 [M]+. SBDPiR731 has been previously 





Figure 36.  1H NMR of SBDPiR731. 
 
2.0.6 (SBDPiR698) 5,5-Difluoro-2,8-bis(4-fluorophenyl)-11-(trifluoromethyl)-5H-
thieno[2',3':4,5] pyrrolo[1,2-c] thieno[2',3':4,5] pyrrolo[2,1-f][1,3,2] diazaborinin-4-
ium-5-uide: To a solution of BDP635 (0.100 g, 0.188 mmol) in toluene, 
tetrahydrofuran, water (30 mL 1:1:1) was added 4-fluorophenyl boronic acid (0.079 g, 
0.57 mmol), Na2CO3 (0.060 g, 0.566 mmol). The reaction was purged with nitrogen gas 
for 10 min.  A catalytic amount of [Pd(PPh3)4] (0.033 g, ~5 mol %) was added and the 
reaction was heated to 80 °C for 2-3 h. After completion of the reaction, the reaction 
was diluted with 10 mL water and extracted with toluene. The combined organic layer 
was washed with water and brine (100 mL each) and dried over anhydrous Na2SO4. The 
dried mixture was purified by silica-gel column chromatography (80:20 
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hexanes:toluene) to afford SBDPiR698 as a dark green solid (0.034 g, 32%).  1H NMR 
(CD2Cl2, 300 MHz): δ= 7.8 (t, J = 7.6, 4H), 7.4 (s, 4H), 7.2(t, J = 8.3, 4H); HRMS EI 
 (m/z): calculated for C26H12BF7N2S2: 560.0423; found 560.0416 [M]+. 
 
 
Figure 37. 1H NMR of SBDPiR698. 
 
2.0.7 (SBDPiR688) 5,5-Difluoro-11-(trifluoromethyl)-2,8-bis (4-(trifluoromethyl) 
phenyl)-5H-thieno[2',3':4,5]pyrrolo[1,2-c]thieno[2',3':4,5]pyrrolo[2,1-
f][1,3,2]diazaborinin-4-ium-5-uide: The method described for SBDPiR698 was 
followed using BDP635 (0.100 g, 0.18 mmol), 4-(trifluoromethyl)phenyl) boronic acid  
(0.100 g, 0.526 mmol), Na2CO3 (0.060 g, 0.566 mmol).  The dried mixture was purified 
by silica-gel column chromatography (90:10 hexanes:ethyl acetate) to afford 
SBDPiR688 as a dark green solid (0.103 g, 28%).  1H NMR (CD2Cl2, 300 MHz): δ= 7.9 
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(d, J = 8.1, 4H), 7.6 (d, J = 3.6, 4H), 7.5 (s, 2H), 7.4 (s, 2H); HRMS EI (m/z): calculated 
for C28H12BF11N2S2 660.0359; found 660.0355 [M]+. 








5-uide 102: SBDPiR740 was synthesized according to reported literature.105 1H NMR 
(acetone-d6, 300 MHz): δ 7.8 (d, J = 9.0 Hz, 4H), 7.5 (s, 2H), 7.4 (s, 2H) 7.0 (d, J = 9.0 
Hz, 4H); HRMS EI (m/z): Calculated for C26H14BF5N2O2S2 556.0510; Found: 556.0520 
[M]+. 
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uide: The method described for SBDPiR698 was followed using BDP635 (0.100 g, 
0.188 mmol), p-tolylboronic acid (0.076 g, 0.560 mmol), Na2CO3 (0.060 g, 0.566 
mmol). The dried mixture was purified by silica-gel column chromatography (70:30 
hexanes:toluene) to afford SBDPiR710 as a dark green solid (0.024 g, 43%).  1H NMR 
(acetone-d6, 300 MHz): δ= 7.67 (d, J = 7.2 Hz, 4H), 7.4 (s, 2H), 7.3 (m, 6H), 2.4 (s, 




















Figure 42.  LRMS EI of SBDPiR710. 
 
2.1.0  (SBDPiR700)  2,8-Bis(4-cyanophenyl)-5,5-difluoro-11-(trifluoromethyl)-5H-
thieno[2',3':4,5]pyrrolo[1,2-c]thieno[2',3':4,5]pyrrolo[2,1-f][1,3,2]diazaborinin-4-ium-5-
uide: The method described for SBDPiR698 was followed using BDP635 (0.100 g, 
0.188 mmol), p-cyanophenyl boronic acid (0.083 g, 0.565 mmol), Na2CO3 (0.080 g, 
0.755  mmol). The dried mixture was purified by silica-gel column chromatography 
(80:20 hexanes: ethyl acetate) to afford SBDPiR700 as a dark green solid (0.024 g, 
37%).  1H NMR (300 MHz, CD2Cl2) δ 0.89 (t, J = 7.2 Hz, 3H), 2.89 (q, 2H), 7.45 (s, 
1H), 7.52 (s, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 8.6 Hz, 2H). HRMS EI (m/z): 















Figure 44. HRMS EI of SBDPiR700. 
 
Absorbance spectra were recorded on a Perkin Elmer lambda 25 UV/Vis spectrometer. 
Steady-state and lifetime fluorescence were measure using a Horiba Jobin Yvon 
UV/Vis/NIR fluorimeter a data station.  Extinction coefficients were determined 
experimentally.  SBDPiR (ca. 1 mg) was dissolved in CHCl3 (5mL) and serially diluted 
to yield variable concentrations (10-6 to 10-7 M). A graph illustrating the slope of 
absorbance versus concentration was plotted and fitted into Beer-Lambert Law.  
Fluorescence quantum yields were estimated according to standard protocol.   
 
Fluorescence lifetimes were obtained by a single exponential curve.  The fluorescence 
emission spectra of SBDPiRs using aza-BODIPY (Фflu= 0.34) as a standard were 
recorded at 25oC. Spectra of diluted SBDPiR and aza-BODIPY were obtained to 
compare their fluorescence emission spectra after excitation of 710 nm. The absorbance 
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of SBDPiR and aza-BODIPY were also obtained.  A graph of fluorescence versus 
absorbance was plotted to generate the gradient (G).  Fluorescence quantum yield was 
calculated using the equation:  
 
Фx = Фstd( Gx/Gstd) (η2x/η2std) 
 
Where the subscripts std and x represent the standard and SBDPiR sample. Ф denotes 
fluorescence quantum yield, G is the gradient obtain from absorbance versus 
fluorescence intensity, and η is equivalent to the refractive index of the solvent.   
 
A Horiba Jobin Yvon UV-Vis/NIR fluorimeter was used to measure the singlet oxygen 
luminescence spectra at 1270 nm. SO quantum yield was determined in CHCl3 with 
[Ru(bipy)3]Cl2 as a reference (ФΔ  = 0.77 in MeOH).   
 
Redox potentials of all SBDPiRs were measured by Dr. Francis D’souza at the 
University of North Texas. Redox potentials were determined with a homemade three 
electrode divided cell consisting of a carbon working electrode, a saturated calomel 
reference electrode (SCE) and a platinum wire counter auxiliary electrode.  A fritted-
glass bridge of low porosity was used to separate the SCE from bulk solution, which 






Chapter III. Application of NIR Dual Functioning BODIPY PS SBDPiR690 
3.0 Introduction 
The evaluation of BODIPY dyes as a novel class of highly active PDT agents has 
recently become of prime interest.99b, 108 As discussed, PDT is a promising non-invasive 
treatment modality that relies on the illumination of a systemically administered 
photosensitizer with visible/NIR light to generate reactive oxygen species, 
predominantly, singlet oxygen (1O2) – a key cytotoxic agent.109 The cytotoxic species as 
a result of PDT performs tumor destruction through various mechanisms. A direct effect 
on cancer cells leads to cell death by necrosis or apoptosis is commonly experienced. 
PDT can also affect tumor vasculature to shut down blood vessels, which consequently 
affects oxygen and nutrient supply to the tumor. The immune system can also be 
affected after PDT and leads to immunostimulatory or immunosuppressive conditions.47 
PDT is in current clinical and preclinical use for the treatment of broad cancerous 
conditions including breast, skin, lung, gastrointestinal tract, colon, ovarian and prostate 
cancers.  
 
Non-malignant diseased states such as age-related macular degeneration (AMD), 
resistant microbial infections and atherosclerosis are treated with PDT. In addition to 
the mechanisms, the outcomes of PDT can be influenced by photosensitizer 
concentration, light dose, drug-light and oxygen availability.27 Antivascular effects of 
PDT are primarily facilitated by the natural tendency of sensitizers to accumulate in 
blood vessels.  Photosensitizers may be referred to as anti-angiogenesis agents, which 
prevent the formation of blood vessels and growth of endothelial cells.  During 
	  76	  
antiangiogenic PDT, short drug administration and light illumination intervals are 
desired.110 Vascular-targeted PDT (VTP) possesses numerous advantages in improved 
efficacy of treatment.  Photosensitizers accumulate in high concentrations within tumor 
blood vessels after intravenous administration. The essential element for photochemical 
reaction, molecular oxygen, is readily available.110-111 Moreover, the role of the vascular 
network to supply oxygen and nutrients to cancer cells make the occlusion of vessels an 
effective approach to treat tumors. Overall, this approach can be used to treat different 
tumor types when considering the shared biochemical and morphological properties of 
cancerous blood vessels.111 
 
Herein, we demonstrate in vitro and in vivo imaging and PDT following a short drug-
light interval protocol of the non-halogenated NIR BODIPY, SBDPiR690. The 
appreciable fluorescence and singlet oxygen properties of SBDPiR690 coupled with the 
in vivo PDT performance shows promise for what is term fluorescence guided - 
vascular targeted PDT (FG-VTP). 
 
 3.1 In vitro Photo and Dark Toxicity 
Varying concentrations of SBDPiR690 from a DMSO stock solution were incubated 
with the cells in the dark for 24 h. Subsequently, the culture medium was removed and 
fresh culture medium was added to each well. The plates were irradiated with a laser 
light source of wavelength 690 nm at a delivered light dose of 5.6 mW cm-2 for 30 min 
(~10 J cm-2). After illumination, the cells were returned to normal medium and 
incubated for an additional 24 h at 37 °C following which percent cell viability was 
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determined using MTT assay. Dark toxicity of SBDPiR690 was determined in similar 
fashion as described above without illumination. All assay experiments were carried out 
in triplicate and an average of the three individual runs are presented. 
Following our assay protocol, colon 26 cells displayed no determinable dark toxicity 
(DT) with SBDPiR690 up to a concentration of 10-4 M. In contrast, illumination with 10 
J cm-2 light dose displayed significant phototoxicity (PT) with IC50 values determined as 
3.2 x 10-6 M (Fig. 45).  
 
The remarkable phototoxicity of SBDPiR690 was encouraging, as this molecule 
contains no halogens as characterized by BODIPY photosensitizers and sets up an 
unprecedented non-halogenated NIR BODIPY structure as a photocytotoxic agent. The 
data clearly demonstrates that we have achieved promising activity (micro molar range) 
with the structurally unique SBDPiR690. The heavy-atom contributions through fusion 
of thiophene units are currently under investigation as the sulfur atoms may influence 
the excited triplet-state population and aid in the production of  moderate singlet oxygen 










Figure 45.  SBDPiR690 Concentration dependent cell survival.	  
 
 
3.2 Drug Bio-distribution and Clearance using SBDPiR690  
Small animal whole body fluorescence imaging was performed with an IVIS Spectrum 
(PerkinElmer Inc.) and the acquired images and fluorescence signals were analyzed 
using Living Image Software v4.0 (PerkinElmer Inc.). Excitation and emission 
wavelengths 675 and 720 nm respectively were used for acquiring in vivo SBDPiRs 
fluorescent images. All images were obtained using an exposure time of 0.5 or 2 s and 
an f/stop of 2. Mice were injected with 2 µmole/kg SBDPiR690 through the retro-
orbital vein and were anesthetized before imaging using the excitation and emission 
wavelength of SBDPiR690 at various time points.  
	  
Ex vivo imaging from excised organs and fluorescence quantification was used to 
demonstrate drug distribution patterns (Fig. 46). Generally, fluorescent signals from 















organs reduced to reach baseline levels by the 24 h time point. It was evident that 
fluorescent signals within the lungs and liver peaked at 3 h and 9 h respectively and 1 h 
for the spleen, indicating high SBDPiR690 concentrations at those time points. 
Furthermore, the heart, kidneys and tumor showed maximum SBDPiR690 
concentrations at 15 min as evidenced by their fluorescence intensity signals and 
subsequently cleared over time. Although a fluorescence signal within the tumor was 
relatively weak it provides useful information for precise drug-light interval towards 
effective PDT.   
	  
 






3.3 Whole Body In Vivo Imaging 
Time dependent in vivo imaging was conducted to monitor the distribution of 
SBDPiR690 in live mouse (Fig. 47). Whole body imaging with SBDPiR690 displayed 
clearance by 24 h and highest fluorescence signal at 30 min, this observation lead to the 
assertion that SBDPiR690 may have minimal skin retention and its maximum 
concentration for treatment would be at the mentioned time point. The relatively small 
size and the freely rotating phenyl rings positioned at the periphery of the BODIPY core 
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3.4 Optical Guided SBDPiR690 Photodynamic Therapy 
Mice (24 mice) were inoculated with colon 26 cells in the head neck area and tumor 
growth was monitored with a digital caliper. Two dimensions, l and w (l, the longest 
axis of tumor; w, the axis perpendicular to l), were used to calculate tumor volume 
(lw2/2). Stock solutions in DMSO (4 mM) and further dilutions in 1% Tween 80 and 
5% dextrose solution to achieve final doses were as follows: Control, SBDPiR690 only, 
light only, 5 µmol/kg SBDPiR690 + 100 mW cm-2 light for 30 min. Samples were 
filtered using 0.2 μm sterile syringe filter. To each mouse, 200 μL of sample was 
injected IV (via intraocular injection). After a 15 min of drug administration mice were 
anesthetized with ketamine 80 mg kg−1 and xylazine 6 mg kg−1, by IP injection. Tumors 
were irradiated with a 690 nm diode laser at 100 mW cm-2 for 30 min (180 J cm-2). 
Tumor size was measured every day after the treatment. Mice recovered after light 
irradiation and returned to normal activity.  
 
Mice were divided into 4 groups: control (negative control), dark control (SBDPiR690 
only), light control (light only), and SBDPiR690-PDT. 200μL of SBDPiR690 (5 
μmole/kg) was intravenously injected into the mice, followed by light illumination [690 
nm diode laser, 100 mW/cm2, 30 min (150 J/cm2)] after 30 min post IV-injection using 
a 690 nm diode laser. [This time point was determined by the above whole body images 
aiming to damage the tumor vasculature]. While the two positive control groups (either 
only hv or SBPiR690) did not show any significant tumor growth delay compared to the 
negative control group, PDT treated group showed dramatic reduction of tumors (Fig. 
48). Mass necrosis localized at the tumor region was evident after 24 - 72 hr after the 
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illumination.  An associated edema and inflammation were observed after 24 h, but 
healed after a few days. Mice were pronounced cured after tissue remodeling with no 












Figure 48. Tumor growth curves in response to various experimental conditions with 





































Figure 49.  Mouse images post-PDT treatment illustrating antitumor effect of PDT with 























Figure 50. Kaplan-Meier Plot of mouse survival days after PDT treatment with 
SBDPiR690 (5 µmole/kg) in Balb/c mice with colon 26 tumor model. 
 
3.5 Conclusion 
Considering the many non-linear variables of the biological system and PDT, we 
successfully translate the advantageous bright and phototoxic properties found within 
test tubes in vitro and in vivo. Furthermore all analogs are applicable to sub-epithelial 
tissue due to their NIR absorption (688-700 nm). The coexisting photophysical 
characteristics permit fusion of photodynamic therapy and diagnosis (theranostics) upon 
administration of a single photosensitizer for optical guided photodynamic therapy.  
 
We essentially use the brightness of the BODIPY PS to determine a drug-light interval 
aimed at hemorrhage of the tumor vasculature. Our results potentially revolutionize 
future design of BODIPY photosensitizers in that (1) NIR absorption can be 
















accomplished through the extended conjugation without altering π-donor and π-
acceptor groups, (2) spin orbit coupling and subsequent ISC can be accomplished 
without HAE, and (3) dual functioning BODIPY PS possesses characteristics required 
for fluorescence guided-vascular targeted PDT.   
 
3.6 Experimental Conditions   
Assays were performed using colon-26 cells. The specified cell line was obtained from 
NCI and cultured in Dubelco minimum essential medium (DMEM) supplemented with 
10% (v/v) fetal calf serum, 1% (v/v) L-glutamine, 50 U mL-1 penicillin, 50 µg mL-1 
stre22221ptomycin. All cells were maintained in 5 % CO2 (v/v) and 21 % O2 (v/v) at 37 
°C. 
 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Oklahoma Health Science Center. Four- to 
six-week-old Balb/c mice (18−20 g, Charles River Laboratories, Inc.) were used for the 
murine tumor model. The mice were inoculated subcutaneously with 2 × 106 colon 26 
cells in PBS (100 μL) on the lower back-neck region. Tumors grew predictably in all 
mice and reached a size of 5 – 6 mm diameter (tumor growth monitored with a digital 
caliper). Within 10 – 14 days after the inoculation, mice were used for imaging.  For ex 
vivo bio distribution studies, mice were euthanized and the tumor, liver, lungs, heart, 





Chapter IV. Functionalization and Photophysics of NIR Dual Functioning 
Photosensitizers  
4.0 Introduction  
 Surgical resection of cancerous tissue continues to be the most efficient and 
conventional therapeutic modality. The success of treatment relies on the surgeon’s 
ability to accurately identify tumor lesions.  Recognition of malignant disease is 
currently achieved by two methods.  First, the abnormalities of cancerous tissue are 
visually discernable as masses and nodules and have a contrasting color, distinct 
morphology, and/or extend beyond the confines of healthy tissue. Second, malignant 
flat lesions are identified intraoperativly through the assistance of fluorescent probes.112 
Passive targeting of current fluorophores allows selective disease accumulation serving 
as disease highlighters. The improved contrast between diseased and normal tissue 
significantly reduce recurrence rate through the removal of otherwise residual cells.27   
 
While the above, termed fluorescence guided surgery, has improved therapeutic 
outcome, the passive diffusion into targets has the disadvantage of background signals 
complicating the delineation of disease tissue.33 Furthermore, many of the current 
probes used for optical guided resection are of the porphyrin scaffold. Porphyrins 
demonstrate selective accumulation, but the photophysical properties, particularly 
brightness, are less than optimal. The scientific community has aimed at improving the 
specificity of porphryins through conjugation of ligands (e.g. folic acid) to fluorescent 
molecules.  These ligands deliver the fluorescent signal directly to over-expressed 
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receptors, which limits the background signal and improving the target concentration.27, 
113 
 
The design dual functioning (bright and phototoxic) NIR BODIPY PS, the application 
of such exquisite optical properties for surgical guidance is advantageous.  The location 
of malignant tissue is a major determinant of therapeutic choice. The removal of 
diseased and/or healthy tissue within sensitive organs, specifically the brain, is 
detrimental to patient quality of life.27 The designed dual functioning PS potentially 
allow surgeons to apply the brightness parameter as a guide for marginal resection and 
eradicate residual disease tissue through the inherent phototoxic power. However, the 
issue of low target-to-background ratio persists in dual functioning photosensitizers 
since these are not targeted.   
 
Hence in this chapter we have functionalized our lead and designed analogs with ester 
functionality at the peripheral and boron center respectively. Upon hydrolysis, the two 
amendments will improve target concentration and bioavailability through increased 
water solubility and disruption of symmetry.  Importantly, the appropriate functional 
groups for conjugation to cancer specific ligand were successfully installed.   
 
4.1 Synthesis of Peripheral Functionalized NIR BODIPY SBDPiR690-COOR 
The peripheral synthetic strategy installs an ethylcarboxylate at the peripheral position 




Scheme 2. Synthesis of SBDPiR690-COOR. 
 
NIR dual functioning PS in that carboxylate groups are moderately deactivating.  The 
synthesis utilizes the BDP635 intermediate as a substrate for Suzuki coupling 
conditions, yielding the phenyl ester SBDPiR690-COOR (Scheme 2).  Suzuki coupling 
reaction conditions were used in the presence of BDP 635 to accomplish the 
functionalization. 
 
4.2 Optical Properties of SBDPiR690-COOR 
 The absorption and emission spectra of SBDPiR690-COOR exhibits signature sharp 
absorption characteristic of BODIPY dyes indicative of the S0 – S1 transition (Fig. 51). 
The inclusion of the carboxylate group bathochromatically shifts the absorbance 
maxima from 690 nm to 705 nm. In turn there was a moderate affect to emission 
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4.3  Extinction Coefficient of SBDP690-COOR  
Extinction coefficients were determined experimentally.  SBDPiR690-COOR (ca. 
1mg) was dissolved in CHCl3 (5mL) and serially diluted to yield variable 
concentrations (10-6 to 10-7).  The absorbance maxima were taken at each concentration 
and a graph illustrating the slope of absorbance versus concentration was plotted and 
fitted into Beer-Lambert Law (Fig. 53). The decrease in extinction coefficient from the 
parent compound was undesired (120,000 M-1cm-1), however the determined 71,745 M-
1cm-1 coefficient is superior to approved PS (Photofrin = 5,000 M-1 cm-1). 






















































4.4  DPBF Method for Detection of Singlet Oxygen SBDPiR690-COOR 
The analogs present were investigated for singlet oxygen generation. Tetrahydrofuran 
(THF) solutions of SBDiR690-COORs were irradiated with broadband light, 400-850 
nm, at 0.5 mW/cm2.  Singlet oxygen generation was approximated experimentally 
through the oxidation of 1,3-diphenylisobenzofuran (DPBF), a known singlet oxygen 
scavenger.99a The presence of reactive oxygen species such as singlet oxygen causes an 
evident decrease in the DPBF absorbance band at 410 nm.   The initial concentrations 
were 5 x 10-6 M of SBDPiR690 and SBDPiR690-COOR along with 90 x 10-6 M of 
DPBF over a period of 16 min. The control represents 90 x 10-6 M DPBF alone in the 
presence of light. The parent compound SBDPiR690 was shown in our previous study 
to have a high singlet oxygen quantum yield  (O Δ) of 0.42, and therefore was used as 
positive control. In reference to the parent compound, SBDPiR690-COOR oxidizes 
DPBF higher relative rate of singlet oxygen, 2.8 fold compared to 2.5 fold by 
SBDPiR690 (Fig. 54). The ability to incorporate reactive functional groups and 
maintain the singlet oxygen generation capability was essential for potentially 




Figure 54. Time-dependent decrease of absorbance (410 nm) by oxidation of DPBF (90 
x 10 -6 M) with SBDPiR690-COOR and SBDPiR690 (5 x 10-6 M) under broad band 
light (400-850 nm at 0.5 mW/cm2).   
 
4.5 Functionalized Intermediate BDP635-COOR 
 In attempt to broaden the application of SBDPiRs, we functionalized BDP635 with an 
ester group, facilitating further conjugation of target specific ligands. The functionalized 
di-bromo intermediate is a prime substrate for Suzuki coupling reactions. This 
established platform with absorption of 642 nm allows us to produce various 
functionalized NIR BODIPY. Moreover the intermediate allows us to apply the 
established ideology for production of functionalized BODIPY analogs with imaging 
and therapeutic capability.  
  
Upon obtaining BDP635 according to the scheme 2, a one-pot reaction BDP635 was 
solvated in dichloromethane (anhydrous) and degassed with nitrogen. The reaction was 
















Lewis acid catalyzed by aluminum chloride allowing substitution of the fluoro groups 
by ethyl 3,4, dihydroxybenzoate in approximately one hour Scheme 3. 
 
Scheme 3. Synthesis of BDP635-COOR. 
 
4.6 Functionalized Theranostic PS SBDPiR688-COOR 
SBDPiR688 analog demonstrates improved Brightness (82,290 M-1 cm-1) and 
Phototoxic Power (99,170 M-1 cm-1) in comparison to the lead compound SBDPiR690, 
26, 400 and 50,400 M-1cm-1 respectively.  We therefore used our functionalized 
intermediate to produce the functionalized SBDPiR688-COOR derivative (Scheme 4).  
In a one-pot reaction, BDP635-COOR, trifluoromethylphenyl boronic acid, and 
Na2CO3 were dissolved in a biphasic mixture of THF, water, and toluene and allowed to 
stir under nitrogen.  Palladium tetrakis-triphenyl phosphine was used to catalyze the 






































4.7 Optical Properties of SBDPiR688-COOR 
 
In comparison to the parent compound the optical properties (absorbance and 
fluorescence) were shifted bathochromatically (Fig. 55). This was expected as the 
conjugation of the molecule was extended.   The extinction coefficient was reduced 
SBDPiR688 (211,000 M-1 cm-1) and SBDPiR688-COOR (197,202 M-1 cm-1) (Fig. 56), 
but very much appreciable in comparison to current approved PS (Photofrin 5,000 M-1 
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4.9 DPBF Method for Detection of Singlet Oxygen of SBDPiR688-COOR 
 
 
The determination of singlet oxygen generation was performed according to procedures 
mentioned above.  The parent compound SBDPiR688 was our most efficient singlet 
oxygen generator. Ability to include functionality and maintain these dual functioning 
properties would be essential in furthering its application for target specific PDT. 
However, modification of the BODIPY core altered the photophysics to exclude singlet 
oxygen generating capabilities (Fig. 58). The structure photophysical property study 
revealed the importance of the HOMO LUMO gap ranging at or above 1.5 to achieve 




























HOMO LUMO energy levels, hypothetically. A more detail investigation into the actual 


















Figure 58. Time-dependent decrease of absorbance (410 nm) by oxidation of DPBF (90 
x 10 -6 M) with SBDPiR688-COOR and SBDPiR688 (5 x 10-6 M) under broadband 



































4.0.1 Conclusion  
 
 
While substitution at the boron center is advantageous for increased aqueous solubility 
and allows functionalization of improved dual functioning analogs, the replacement of 
fluorine affects the singlet oxygen generating capability.  Therefore, modification at the 
peripheral is a valid method for functionalization of the newly designed molecules. 
Upon conversion to the carboxylic acid, SBDPiR690-COOR can be tethered to desired 
targets for imaging and therapeutic usage. 
 




f][1,3,2]diazaborinin-4-ium-5-uide: BDP635 (0.100 g, 0.190 mmol) was synthesized 
according to Scheme 1 and dissolved in toluene, tetrahydrofuran, water (30 mL 1:1:1). 
Commercially available 4-ethoxycarbonylphenyl boronic acid (0.109 g, 0.515 mmol  ) 
and Na2CO3 (0.080 g, 0.756 mmol) was added and the reaction was purged with 
nitrogen gas for 10 min. Pd(PPh3)4 (0.022 g, check this wt ~5 mol %) was used to 
catalyzed the reaction at 80 °C for 2-3 h. Upon completion, the reaction was diluted 
with 10 mL water and extracted with toluene. The combined organic layer was washed 
with water and brine (100 mL each) and dried over anhydrous Na2SO4. The dried 
mixture was purified by silica-gel column chromatography (1:99) hexanes:toluene) to 
afford SBDPiR690-COOR as a dark green solid (0.028 g, 22%). 1H NMR (300 MHz, 
CD2Cl2) δ 1.14 (t, J = 6.9 Hz, 3H), 4.41 (q, 2H), 7.42 (s, 1H), 7.53 (s, 1H), 7.85 (d, J = 
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8.4 Hz, 2H), 8.13 (d, J = 8.6 Hz, 2H). HRMS EI (m/z): calculated for C32H22BF5N2O4S2 
668.1034; found 668.1010 [M]+. 
 
 








Figure 60. HRMS EI of SBDPiR690-COOR. 
 
4.0.4  (BDP635-COOR) 2',8'-Dibromo-5-(ethoxycarbonyl)-11'-(trifluoromethyl)spiro 
[benzo[d][1,3,2]dioxaborole-2,5'- thieno[2',3':4,5]pyrrolo[1,2-c]thieno [2',3':4,5]pyrrolo 
[2,1-f][1,3,2]diazaborinin]-4'-ium-12-uide: BDP635 (0.050g, 0.094 mmol) was 
dissolved in dry dichloromethane (20 mL) and stirred under argon for 20 min.  Then 
AlCl3 (0.062 g, 0.466 mmol) was added and the solution was further stirred for 15 min 
before addition of ethyl 3,4-dihydroxybenzoate (0.085 g, 0.467 mmol). The mixture was 
stirred for 20 min and the solvent was evaporated under reduced pressure. The crude 
product was purified on silica gel with CH2Cl2/ Hexanes 1:1 to give a brown solid 
BDP635-COOR (0.027 g, 42%).  1H NMR (300 MHz, CD2Cl2) δ 1.31 (t, J = 7.0 Hz, 
3H), 4.27 (q, 2H), 6.19 (s, 1H), 6.78 (d, J = 8.1 Hz, 1H), 7.32 (s, 1H), 7.42 (s, 1H), 7.61 




Figure 61. 1H NMR of BDP635-COOR. 
 






12-uide:  To a solution of BDP635-COOR (0.050 g, 0.094 mol) in toluene, 
tetrahydrofuran, water (15mL 1:1:1) was added 4-trifluormethylphenylboronic acid 
(0.042 g, 0.223 mmol), Na2CO3 (0.031 g, 0.298 mmol). The reaction was purged with 
nitrogen gas for 10 min.  A catalytic amount of [Pd(PPh3)4] (0.010 g,( ~10 mol %) was 
added and the reaction was heated to 80 oC for 2-3 h. After completion of the reaction as 
judged by TLC, the reaction was diluted with 10 mL water and extracted with toluene. 
The combined organic layer was washed with water and brine (100 mL each) and dried 
over anhydrous Na2SO4. The dried mixture was purified by silica-gel column 
chromatography (60:40) hexanes:toluene) to afford SBDPiR88-COOR as a dark green 
solid (0.018 g, 30% ).  1H NMR (300 MHz, CD2Cl2) δ= 1.41 (t, J = 7.0 Hz, 3H), 4.40(q, 
2H), 6.56 (s, 2H), 6.96 (d, J = 8.1 Hz, 1H), 7.50 (s, 1H), 7.58 (s, 1H), 7.60 (s, 2H), 7.65 
(s, 2H), 7.67 (s, 1H), 7.8 (d, J=6.6, 1H). HRMS EI (m/z): calculated for calculated for 
C37H20BF9N2O4S2 802.0814; found 802.0834 [M]+. 
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Figure 63. 1H NMR of SBDPiR688-COOR. 
Figure 64. HRMS EI of SBDPiR688-COOR 
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Chapter V. Conclusion and Perspective  
 The ability to image and treat intact malignant tissue non-invasively is an emerging 
modality. Preclinical and clinical investigations reveal the advantages of fluorescence 
imaging and PDT for dependable prognosis and curing of disease, specifically cancer.  
The clinical slow progression of fluorescence imaging and PDT is a result of the 
difficulty in optimizing the variable components of PDT for treatment.  Furthermore, 
the currently approved light sources and photosensitizers, while effective, do not 
illustrate stark improvements in comparison to conventional treatments (chemotherapy 
and radiotherapy). To further the mainstream expansion of theranostic PDT, efficient 
NIR absorbing fluorescent photosensitizers are needed.  
 
The ideal agent should possess 1) sharp absorption and emission bands, 2) a high molar 
extinction coefficient, 3) appreciable singlet oxygen and fluorescence quantum yields, 
and 4) reactivity for functionalization.  Currently approved PSs lack these 
characteristics, which limits their application to surface malignancies.  Furthermore, 
development remains focused on the design of separate imaging and therapeutic agents 
for the accomplishment of two objectives.  The combination of imaging and therapy in 
one setting is known as theranostics.  The fusion of the two modalities offers imaging 
and monitoring of diseased tissue, biodistribution, and therapeutic efficacy. Further 
development includes the ability to fine tune therapy and dose amidst application.  Also, 
the ability to characterize tissue pre, during, and post treatment will offer a patient 
personalized therapeutic approach for disease.  
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In this dissertation, the design, synthesis, and application of NIR dual functioning 
BODIPY analogs serve to:  1) understand the contributing factors for yielding both 
appreciable fluorescence and singlet oxygen quantum yields in the versatile BODIPY 
PS and 2) effectively apply the brightness for imaging of bio distribution for 
determining the optimal drug light interval for vascular targeting photodynamic therapy.  
NIR BODIPY dyes (imaging agents) are primarily achieved through extended 
conjugation of the core in addition to possessing a donor-π-acceptor system.  With these 
in place NIR BODIPY dyes can be converted to photosensitizers (photodynamic agents) 
through inclusion of heavy atoms such as bromine and iodine, chemically inducing 
intersystem crossing.  However, this method significantly diminishes the fluorescence 
quantum yield, brightness, and overall imaging capability.   
 
The dissertation successfully demonstrates NIR absorbing BODIPY analogs through 
fusion of the pyrrole and thiophene rings proceeding carbon-carbon coupling of the 
thiophene moiety to phenyl rings.  The methodology is unique in that we exclude the 
donor-π-acceptor acceptor principle, which prevents the production of singlet oxygen 
without heavy atom assistance. Incorporation of neutral to electron-withdrawing groups 
facilitates a theranostic approach with brighter photodynamic NIR agents.   
 
While the present photosensitizers are rare in their dual functionality, the agents are not 
without limitation.  As seen in our whole body images, the current molecules exhibit 
non-specific distribution. The brief localization of the drug is a result of low-density 
lipophilic proteins acting as a carrier to the tumor site and home via the enhance 
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permeation and retention effect associated with passive diffusion of malignant tissue.47 
Therefore our agents, while effective, lack distinct selectivity as with conventional 
therapy methods.   We used the brightness to determine the appropriate irradiation time, 
but the methodology of vascular targeting through short (15 to 30 min) drug light 
intervals has been firmly established within the PDT community.110-111 
 
The purpose of tumor vascular targeting is to selectively alter the tumor vasculature. 
The vasculature is a prime target in that disrupting the circulatory function shutdowns 
nutrient supply and moreover eliminates its means of spreading cancer cells to nearby 
healthy organs and tissue. Efforts to incorporate carboxylate synthons facilitate a 
solution to the selectivity issue.  However, while various vascular markers have shown 
to be overexpressed, an absolute biomarker for tumor vasculature has yet to be 
discovered. Furthermore, conjugation of BODIPY potentially alters the natural 
pharmacokinetics of target ligands and resulting in extensive circulation and low 
clearance rates.  These together result in dark toxicity and affect imaging efficacy due to 
increased background signals.114 
 
In the event an absolute marker is discovered, the optimal PS would not only be NIR 
targeted but exists as a quenched precursor that is activated at the target site.  This 
approach allows significant target-to-background ratios.55 Otherwise an extensive 
structure activity relationship would be advantageous for locating the optimal 
hydrophobicity for increasing selective uptake and photosensitizing efficacy. This 
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particular SAR was key for identifying structure modification of porphryin-based 
scaffolds.96  
 
PDT has been approved for more than 25 years in respect to oncology; however, is not 
exercised as a mainstream therapy.  This is in part due to the above facts. Overall, the 
capacities in which established drug light combinations have been applied (i.e. 
photodynamic therapy) hold no clear advantage over conventional therapies.  As with 
our dual functioning PS, advancements have only been successful at demonstrating the 
viability of photodynamic therapy.  Furthermore, failure to establish optimal routine 
variables for the multifaceted PDT dissuades clinicians’ interests.49c However, it is the 
multi components that enforce a personalized approach, which is vital for treating the 
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 Figure 65. Cyclic voltammogram and differential pulse voltammetry. 
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Table 5. X-ray crystal structure of SBDPiR690 
 
Crystal data and structure refinement for SBDPiR690. 
Identification code  p21c 
Empirical formula  C26 H14 B F5 N2 S2 
Formula weight  524.32 
Temperature  200(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
 Space group  P 21/c 
Unit cell dimensions a = 13.976(3) Å α = 90°. 
 b = 11.672(3) Å β= 111.368(4)°. 
 c = 14.646(4) Å γ = 90°. 
Volume 2224.9(9) Å3 
Z 4 
Density (calculated) 1.565 Mg/m3 
Absorption coefficient 0.301 mm-1 
F(000) 1064 
Crystal size 0.20 x 0.16 x 0.03 mm3 
Theta range for data collection 1.56 to 26.02°. 
Index ranges -17<=h<=17, -14<=k<=14, -18<=l<=18 
Reflections collected 19787 
Independent reflections 4387 [R(int) = 0.1118] 
Completeness to theta = 26.02° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9916 and 0.9417 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4387 / 0 / 325 
Goodness-of-fit on F2 1.025 
Final R indices [I>2sigma(I)] R1 = 0.0657, wR2 = 0.1128 
R indices (all data) R1 = 0.1606, wR2 = 0.1407 
Largest diff. peak and hole 0.428 and -0.339 e.Å-3 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for  SBDPiR690. U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
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 x y z U(eq) 
________________________________________________________________________________   
S(1) 857(1) 6931(1) 5385(1) 58(1) 
F(1) 3459(2) 3260(2) 5971(2) 64(1) 
N(1) 2124(2) 4322(3) 4771(2) 41(1) 
C(1) 1669(3) 4996(3) 5243(3) 41(1) 
B(1) 2594(4) 3146(4) 5115(3) 46(1) 
S(2) 3879(1) 110(1) 3302(1) 62(1) 
F(2) 1897(2) 2438(2) 5309(2) 65(1) 
N(2) 2875(3) 2673(3) 4287(2) 46(1) 
C(2) 1428(3) 4884(3) 6082(3) 46(1) 
F(3) 3722(3) 5178(3) 2652(2) 113(1) 
C(3) 984(3) 5854(3) 6260(3) 45(1) 
F(4) 2326(3) 4592(3) 1688(2) 107(1) 
C(4) 1411(3) 6056(3) 4760(3) 44(1) 
F(5) 2418(3) 6128(3) 2440(2) 134(2) 
C(5) 1718(3) 6041(4) 3980(3) 53(1) 
C(6) 2172(3) 4945(3) 3978(3) 45(1) 
C(7) 2613(3) 4427(4) 3369(3) 48(1) 
C(8) 2944(3) 3289(4) 3495(3) 48(1) 
C(9) 3324(3) 2536(4) 2940(3) 54(1) 
C(10) 3471(3) 1492(4) 3387(3) 50(1) 
C(11) 3684(3) -290(4) 4377(3) 51(1) 
C(12) 3318(3) 591(3) 4776(3) 49(1) 
C(13) 3197(3) 1591(3) 4218(3) 44(1) 
C(14) 619(3) 6048(4) 7063(3) 52(1) 
C(15) -62(4) 6937(4) 7024(4) 69(1) 
C(16) -428(4) 7046(5) 7786(5) 86(2) 
C(17) -132(5) 6312(6) 8560(5) 92(2) 
C(18) 552(5) 5464(5) 8606(4) 86(2) 
C(19) 937(4) 5334(4) 7869(3) 72(2) 
C(20) 3876(3) -1464(4) 4767(3) 57(1) 
C(21) 3579(4) -1787(4) 5534(3) 64(1) 
C(22) 3783(4) -2869(4) 5950(4) 71(1) 
C(23) 4282(4) -3653(4) 5595(4) 80(2) 
C(24) 4583(4) -3346(4) 4832(4) 77(2) 
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C(25) 4392(4) -2260(4) 4407(3) 68(1) 






Bond lengths [Å] and angles [°] for SBDPiR690. 
_____________________________________________________  
S(1)-C(4)  1.732(4) 
S(1)-C(3)  1.757(4) 
F(1)-B(1)  1.394(5) 
N(1)-C(1)  1.350(4) 
N(1)-C(6)  1.392(4) 
N(1)-B(1)  1.526(5) 
C(1)-C(2)  1.394(5) 
C(1)-C(4)  1.405(5) 
B(1)-F(2)  1.383(5) 
B(1)-N(2)  1.509(5) 
S(2)-C(10)  1.731(4) 
S(2)-C(11)  1.756(4) 
N(2)-C(13)  1.357(5) 
N(2)-C(8)  1.397(5) 
C(2)-C(3)  1.361(5) 
C(2)-H(2A)  0.9500 
F(3)-C(26)  1.315(6) 
C(3)-C(14)  1.460(5) 
F(4)-C(26)  1.306(5) 
C(4)-C(5)  1.358(5) 
F(5)-C(26)  1.288(5) 
C(5)-C(6)  1.428(5) 
C(5)-H(5A)  0.9500 
C(6)-C(7)  1.394(5) 
C(7)-C(8)  1.396(5) 
C(7)-C(26)  1.506(6) 
C(8)-C(9)  1.425(5) 
C(9)-C(10)  1.363(6) 
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C(9)-H(9A)  0.9500 
C(10)-C(13)  1.408(5) 
C(11)-C(12)  1.370(5) 
C(11)-C(20)  1.472(6) 
C(12)-C(13)  1.399(5) 
C(12)-H(12A)  0.9500 
C(14)-C(19)  1.380(6) 
C(14)-C(15)  1.395(6) 
C(15)-C(16)  1.394(7) 
C(15)-H(15A)  0.9500 
C(16)-C(17)  1.359(7) 
C(16)-H(16A)  0.9500 
C(17)-C(18)  1.361(7) 
C(17)-H(17A)  0.9500 
C(18)-C(19)  1.378(6) 
C(18)-H(18A)  0.9500 
C(19)-H(19A)  0.9500 
C(20)-C(21)  1.385(6) 
C(20)-C(25)  1.392(6) 
C(21)-C(22)  1.385(6) 
C(21)-H(21A)  0.9500 
C(22)-C(23)  1.364(6) 
C(22)-H(22A)  0.9500 
C(23)-C(24)  1.377(7) 
C(23)-H(23A)  0.9500 
C(24)-C(25)  1.394(7) 
C(24)-H(24A)  0.9500 





































































































Symmetry transformations used to generate equivalent atoms:  
  
Anisotropic displacement parameters  (Å2x 103) for SBDPiR690.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 72(1)  42(1) 63(1)  0(1) 27(1)  13(1) 
F(1) 81(2)  74(2) 36(1)  7(1) 23(1)  32(2) 
N(1) 55(2)  37(2) 36(2)  7(2) 22(2)  8(2) 
C(1) 50(3)  38(2) 38(2)  -1(2) 20(2)  2(2) 
B(1) 62(4)  42(3) 42(3)  3(2) 28(3)  10(3) 
S(2) 67(1)  69(1) 56(1)  -26(1) 29(1)  4(1) 
F(2) 95(2)  41(1) 83(2)  13(1) 62(2)  15(1) 
N(2) 58(3)  44(2) 40(2)  0(2) 25(2)  8(2) 
C(2) 55(3)  46(3) 43(2)  0(2) 23(2)  6(2) 
F(3) 89(3)  169(3) 90(2)  46(2) 45(2)  -23(2) 
C(3) 44(3)  43(2) 47(2)  -8(2) 17(2)  2(2) 
F(4) 152(3)  128(3) 40(2)  1(2) 34(2)  -54(2) 
	  130	  
C(4) 49(3)  37(2) 47(2)  0(2) 18(2)  1(2) 
F(5) 246(5)  95(2) 116(3)  55(2) 131(3)  55(3) 
C(5) 60(3)  48(3) 46(2)  9(2) 15(2)  -1(2) 
C(6) 49(3)  49(3) 39(2)  6(2) 17(2)  2(2) 
C(7) 52(3)  58(3) 36(2)  3(2) 17(2)  -4(2) 
C(8) 53(3)  59(3) 38(2)  1(2) 22(2)  2(2) 
C(9) 53(3)  74(3) 40(2)  -13(2) 23(2)  -4(3) 
C(10) 49(3)  60(3) 42(2)  -16(2) 17(2)  0(2) 
C(11) 47(3)  55(3) 52(2)  -16(2) 19(2)  0(2) 
C(12) 57(3)  48(3) 46(2)  -8(2) 23(2)  8(2) 
C(13) 51(3)  49(3) 36(2)  -6(2) 18(2)  5(2) 
C(14) 44(3)  58(3) 56(3)  -19(2) 20(2)  0(2) 
C(15) 60(3)  67(3) 81(3)  -31(3) 25(3)  -1(3) 
C(16) 66(4)  90(4) 114(5)  -58(4) 46(4)  -7(3) 
C(17) 80(5)  124(6) 87(4)  -61(4) 50(4)  -35(4) 
C(18) 91(5)  117(5) 63(3)  -17(3) 41(3)  1(4) 
C(19) 80(4)  93(4) 55(3)  -7(3) 41(3)  17(3) 
C(20) 51(3)  49(3) 67(3)  -25(2) 16(3)  1(2) 
C(21) 65(4)  48(3) 78(3)  -9(3) 25(3)  4(3) 
C(22) 71(4)  48(3) 88(4)  -8(3) 22(3)  4(3) 
C(23) 72(4)  50(3) 107(4)  -21(3) 20(4)  -2(3) 
C(24) 62(4)  56(4) 105(4)  -38(3) 20(3)  8(3) 
C(25) 55(3)  60(3) 81(3)  -26(3) 14(3)  10(3) 





Hydrogen coordinates (x 104) and isotropic  displacement parameters (Å2x 10 3) 
for SBDPiR690. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2A) 1557 4215 6479 56 
H(5A) 1645 6644 3524 63 
H(9A) 3452 2727 2364 64 
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H(12A) 3167 531 5356 59 
H(15A) -271 7457 6488 83 
H(16A) -896 7646 7764 104 
H(17A) -401 6391 9067 110 
H(18A) 766 4956 9150 104 
H(19A) 1425 4749 7917 86 
H(21A) 3224 -1251 5783 77 
H(22A) 3576 -3063 6481 85 
H(23A) 4421 -4400 5870 96 
H(24A) 4932 -3892 4587 93 




















Figure 67. HPLC Chromatogram of SBDPiR690: mobile phase = 100% acetonitrile, 
















Figure 68. HPLC Chromatogram of SBDPiR698: mobile phase = 100% acetonitrile, 











Figure 69. HPLC Chromatogram of SBDPiR688: mobile phase = 100% acetonitrile, 
































Figure 70. HPLC Chromatogram of SBDPiR710: mobile phase = 100% acetonitrile, 
flow rate 0.25 ml/min, detection at 254 nm, rt (retention time) = 35.58 min; purity = 99 
%.  
 
 
 
 
 
 
 
 
 
 
 
